imidazolidines - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	imidazolidines	go back to main search page
Accession:	CHEBI:38261	browse the term

show annotations for term's descendants Sort by:
Rat (1007) Mouse (1004) Human (1007) Chinchilla (0) Bonobo (0) Dog (3) Squirrel (0) Pig (2) Green Monkey (0) Naked Mole-rat (0) All
Genes (1007)

4-hydroxyphenytoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions

UGT1A1 protein results in increased glucuronidation of and results in decreased activity of hydroxyphenytoin

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A5

multiple interactions

UGT1A4 protein results in increased glucuronidation of and results in decreased activity of hydroxyphenytoin

NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions

UGT1A6 protein results in increased glucuronidation of and results in decreased activity of hydroxyphenytoin

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

multiple interactions

UGT1A9 protein results in increased glucuronidation of and results in decreased activity of hydroxyphenytoin

NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465

7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

prostaglandin D2 receptor

multiple interactions

BW 245C binds to and results in increased activity of PTGDR protein; BW 245C inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]

PMID:9579725 PMID:15528449 PMID:20719937

NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679

G

transforming growth factor, beta 1

decreases response to substance

BW 245C results in decreased susceptibility to TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

allantoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

interleukin 1 beta

increases secretion
decreases secretion

Allantoin results in increased secretion of IL1B protein
Allantoin results in decreased secretion of IL1B protein

PMID:30654793 PMID:32382552

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

increases secretion
decreases secretion

Allantoin results in increased secretion of IL6 protein
Allantoin results in decreased secretion of IL6 protein

PMID:30654793 PMID:32382552

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

leptin receptor

affects abundance

LEPR affects the abundance of Allantoin

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

nitric oxide synthase 2

decreases expression
increases expression

Allantoin results in decreased expression of NOS2 protein
Allantoin results in increased expression of NOS2 protein

PMID:30654793 PMID:32382552

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

prostaglandin-endoperoxide synthase 2

decreases expression

Allantoin results in decreased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

transforming growth factor, beta 1

increases expression

Allantoin results in increased expression of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

decreases secretion
increases secretion

Allantoin results in decreased secretion of TNF protein
Allantoin results in increased secretion of TNF protein

PMID:30654793 PMID:32382552

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular endothelial growth factor A

increases expression
affects secretion

Allantoin results in increased expression of VEGFA protein
Allantoin affects the secretion of VEGFA protein

PMID:30654793 PMID:32382552

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

xanthine dehydrogenase

multiple interactions

[2,2,5,7,8-pentamethyl-1-hydroxychroman results in decreased activity of XDH protein] which results in decreased abundance of Allantoin

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

Azimilide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity
multiple interactions

azimilide results in decreased activity of KCNH2 protein
Acids inhibits the reaction [azimilide results in decreased activity of KCNH2 protein]; azimilide promotes the reaction [naringenin results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [azimilide results in decreased activity of KCNH2 protein]; Potassium inhibits the reaction [azimilide results in decreased activity of KCNH2 protein]

PMID:15821840 PMID:16960444 PMID:18057881

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

BW A868C

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

prostaglandin D2 receptor

multiple interactions

BW A868C binds to and results in decreased activity of PTGDR protein
BW A868C binds to and results in increased activity of PTGDR protein; BW A868C inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]

PMID:9579725 PMID:15528449

NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679

creatinine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

basic helix-loop-helix ARNT like 1

increases abundance

BMAL1 gene mutant form results in increased abundance of Creatinine

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

collagen type II alpha 1 chain

multiple interactions

[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

isocitrate dehydrogenase (NADP(+)) 2

multiple interactions
increases abundance

Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Creatinine]

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

leptin receptor

affects abundance
multiple interactions
increases abundance

LEPR affects the abundance of Creatinine
Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Creatinine]; swietenine inhibits the reaction [LEPR gene mutant form results in increased abundance of Creatinine]

PMID:20567778 PMID:29988851 PMID:36066211

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

NFE2 like bZIP transcription factor 2

multiple interactions

[NFE2L2 protein affects the susceptibility to ochratoxin A] which results in increased abundance of Creatinine

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

prostaglandin-endoperoxide synthase 1

multiple interactions

[SC 560 results in decreased activity of PTGS1 protein] which results in increased abundance of Creatinine

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

solute carrier family 47 member 1

multiple interactions

Creatinine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637

G

solute carrier family 47 member 2

multiple interactions

Creatinine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904

G

superoxide dismutase 2

decreases abundance

SOD2 protein results in decreased abundance of Creatinine

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

dantrolene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2

affects transport

ABCG2 protein affects the transport of Dantrolene

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

angiotensin converting enzyme 2

increases expression

Dantrolene results in increased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

activating transcription factor 4

decreases expression
multiple interactions

Dantrolene results in decreased expression of ATF4 protein
Dantrolene affects the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; Dantrolene inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein]; Dantrolene promotes the reaction [Thapsigargin results in increased expression of ATF4 mRNA]

PMID:15921666 PMID:32578922

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

BCL2 associated X, apoptosis regulator

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of BAX mRNA]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

increases expression

Dantrolene results in increased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 11

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of BCL2L11 mRNA]

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

brain-derived neurotrophic factor

multiple interactions

Dantrolene inhibits the reaction [Oxygen deficiency results in increased secretion of BDNF protein]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

calpain 1

decreases expression

Dantrolene results in decreased expression of CAPN1 mRNA; Dantrolene results in decreased expression of CAPN1 protein

NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177

G

calpain 2

decreases expression

Dantrolene results in decreased expression of CAPN2 mRNA; Dantrolene results in decreased expression of CAPN2 protein

NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969

G

calpain 3

decreases expression

Dantrolene results in decreased expression of CAPN3 mRNA; Dantrolene results in decreased expression of CAPN3 protein

NCBI chr 3:107,407,518...107,457,858
Ensembl chr 3:107,407,850...107,457,858

G

caspase 3

multiple interactions

Dantrolene inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]
Dantrolene inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]

PMID:17079870 PMID:23022152

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

Dantrolene inhibits the reaction [Indomethacin results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

C-C motif chemokine ligand 2

decreases expression

Dantrolene results in decreased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

affects expression

Dantrolene affects the expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-X-C motif chemokine ligand 2

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of CXCL2 mRNA]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Dantrolene inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

Dantrolene inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

DNA-damage inducible transcript 3

decreases phosphorylation
multiple interactions

Dantrolene results in decreased phosphorylation of DDIT3 protein
Dantrolene inhibits the reaction [Halothane results in increased expression of DDIT3 mRNA]; Dantrolene promotes the reaction [perfluorooctanoic acid results in increased expression of DDIT3 mRNA]; Dantrolene promotes the reaction [perfluorooctanoic acid results in increased expression of DDIT3 protein]

PMID:15921666 PMID:32578922 PMID:32795494

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

endothelin 1

decreases activity

Dantrolene results in decreased activity of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

eukaryotic translation initiation factor 2 alpha kinase 3

decreases phosphorylation

Dantrolene results in decreased phosphorylation of EIF2AK3 protein

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

decreases phosphorylation
multiple interactions

Dantrolene results in decreased phosphorylation of EIF2S1 protein
Dantrolene inhibits the reaction [tributyltin results in increased phosphorylation of EIF2S1 protein]

PMID:15921666 PMID:23743301

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

FKBP prolyl isomerase 1A

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of FKBP1A mRNA]

NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743

G

FKBP prolyl isomerase 1B

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of FKBP1B mRNA]

NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653

G

glial fibrillary acidic protein

multiple interactions

Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of GFAP protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of GFAP protein]

PMID:21863293 PMID:21879721

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glutamic--pyruvic transaminase

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

heme oxygenase 1

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

homer scaffold protein 1

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of HOMER1 mRNA]

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

heat shock protein family A (Hsp70) member 5

multiple interactions

Dantrolene inhibits the reaction [tributyltin results in increased expression of HSPA5 protein]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interferon gamma

multiple interactions

Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IFNG mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1

decreases response to substance

Dantrolene results in decreased susceptibility to IGF1 protein

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 2

decreases response to substance

Dantrolene results in decreased susceptibility to IGF2 protein

NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018

G

interleukin 10

multiple interactions
affects expression

Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]]
Dantrolene affects the expression of IL10 protein

PMID:17707769 PMID:25051504

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

affects expression
multiple interactions

Dantrolene affects the expression of IL1B mRNA
Dantrolene inhibits the reaction [Halothane results in increased expression of IL1B mRNA]

PMID:25051504 PMID:32795494

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Dantrolene results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium inwardly-rectifying channel, subfamily J, member 11

multiple interactions

Dantrolene inhibits the reaction [KCNJ11 protein mutant form results in increased abundance of Calcium]

NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082

G

leptin

decreases expression

Dantrolene results in decreased expression of LEP protein

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

myocyte enhancer factor 2a

multiple interactions

Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A protein]

NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948

G

myocyte enhancer factor 2C

multiple interactions

Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C protein]

NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880

G

myosin heavy chain 7

multiple interactions

Dantrolene inhibits the reaction [Caffeine results in increased expression of MYH7 mRNA]

NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217

G

neurofilament light chain

multiple interactions

Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFL protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFL protein]

PMID:21863293 PMID:21879721

NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793

G

neurofilament medium chain

multiple interactions

Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFM protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFM protein]

PMID:21863293 PMID:21879721

NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755

G

natriuretic peptide A

multiple interactions

Dantrolene inhibits the reaction [Caffeine results in increased expression of NPPA mRNA]

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide B

multiple interactions

Dantrolene inhibits the reaction [Caffeine results in increased expression of NPPB mRNA]

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

ryanodine receptor 1

multiple interactions

Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]]; Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] which results in increased transport of Calcium]

NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812

G

ryanodine receptor 2

multiple interactions

Dantrolene inhibits the reaction [Caffeine promotes the reaction [RYR2 protein results in increased secretion of Calcium]]

NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142

G

S100 calcium binding protein A8

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of S100A8 mRNA]

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of S100A9 mRNA]

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

steroidogenic acute regulatory protein

multiple interactions

Dantrolene inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

tumor necrosis factor

decreases expression
multiple interactions

Dantrolene results in decreased expression of TNF protein
Dantrolene inhibits the reaction [Halothane results in increased expression of TNF mRNA]

PMID:11236903 PMID:32795494

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular cell adhesion molecule 1

multiple interactions

Dantrolene inhibits the reaction [Halothane results in increased expression of VCAM1 mRNA]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vimentin

multiple interactions

Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of VIM protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of VIM protein]

PMID:21863293 PMID:21879721

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

X-box binding protein 1

multiple interactions

Dantrolene inhibits the reaction [perfluorooctanoic acid results in increased expression of XBP1 mRNA alternative form]; Dantrolene inhibits the reaction [Thapsigargin results in increased expression of XBP1 mRNA alternative form]

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

enzalutamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate aminotransferase

decreases expression

enzalutamide results in decreased expression of AADAT mRNA

NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332

G

ATP binding cassette subfamily C member 4

decreases expression

enzalutamide results in decreased expression of ABCC4 mRNA

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

acyl-CoA synthetase medium-chain family member 1

decreases expression

enzalutamide results in decreased expression of ACSM1 mRNA

NCBI chr 1:173,985,715...174,020,565
Ensembl chr 1:173,984,672...174,025,495

G

ADAM metallopeptidase domain 10

affects expression

enzalutamide affects the expression of ADAM10 mRNA

NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889

G

ADAM metallopeptidase domain 17

affects expression

enzalutamide affects the expression of ADAM17 mRNA

NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639

G

ADP-ribose/CDP-alcohol diphosphatase, manganese-dependent

decreases expression

enzalutamide results in decreased expression of ADPRM mRNA

NCBI chr10:51,732,073...51,744,635
Ensembl chr10:51,731,993...51,744,635

G

ALF transcription elongation factor 3

decreases expression

enzalutamide results in decreased expression of AFF3 mRNA

NCBI chr 9:40,399,099...40,856,716
Ensembl chr 9:40,404,375...40,857,247

G

aldehyde dehydrogenase 1 family, member A3

decreases expression

enzalutamide results in decreased expression of ALDH1A3 mRNA

NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436

G

alpha-kinase 2

decreases expression

enzalutamide results in decreased expression of ALPK2 mRNA

NCBI chr18:58,775,603...58,906,150
Ensembl chr18:58,775,605...58,906,258

G

annexin A4

affects expression

enzalutamide affects the expression of ANXA4 mRNA

NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161

G

aph-1 homolog A, gamma secretase subunit

affects expression

enzalutamide affects the expression of APH1A mRNA

NCBI chr 2:183,437,676...183,443,113
Ensembl chr 2:183,438,434...183,441,955

G

aph-1 homolog B, gamma secretase subunit

affects expression

enzalutamide affects the expression of APH1B mRNA

NCBI chr 8:67,429,198...67,454,735
Ensembl chr 8:67,429,198...67,450,243

G

amyloid beta precursor protein

affects expression

enzalutamide affects the expression of APP mRNA

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

androgen receptor

multiple interactions
decreases activity
decreases response to substance
decreases expression

[enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]]; [enzalutamide co-treated with Niclosamide] results in decreased expression of AR protein; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR mRNA; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR mRNA alternative form; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR protein; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of AR protein alternative form; [nirogacestat results in increased susceptibility to enzalutamide] which results in decreased expression of AR protein; enzalutamide binds to and results in decreased localization of and results in decreased activity of AR protein; enzalutamide inhibits the reaction [Dihydrotestosterone affects the localization of AR protein]; enzalutamide inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to MYC enhancer]]; enzalutamide inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; enzalutamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; Niclosamide inhibits the reaction [AR protein alternative form results in decreased susceptibility to enzalutamide]
enzalutamide results in decreased activity of AR protein
AR alternative form results in decreased susceptibility to enzalutamide; AR protein alternative form results in decreased susceptibility to enzalutamide; AR protein results in decreased susceptibility to enzalutamide
enzalutamide results in decreased expression of AR protein; enzalutamide results in decreased expression of AR protein alternative form

PMID:19359544 PMID:24740322 PMID:24759320 PMID:25908785 PMID:25970160 More...

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

alpha-2-glycoprotein 1, zinc-binding

decreases expression

enzalutamide results in decreased expression of AZGP1 mRNA

NCBI chr12:16,930,990...16,939,333
Ensembl chr12:16,931,024...16,939,091

G

baculoviral IAP repeat-containing 5

multiple interactions

enzalutamide promotes the reaction [Niclosamide results in decreased expression of BIRC5 protein]

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

bone morphogenetic protein receptor type 1B

decreases expression

enzalutamide results in decreased expression of BMPR1B mRNA

NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368

G

similar to human chromosome 1 open reading frame 116

decreases expression

enzalutamide results in decreased expression of C1ORF116 mRNA

NCBI chr13:42,187,442...42,201,432
Ensembl chr13:42,188,609...42,201,426

G

caspase 3

multiple interactions
decreases expression

enzalutamide promotes the reaction [NVP-BHG712 results in increased cleavage of CASP3 protein]
enzalutamide results in decreased expression of CASP3 protein

PMID:32184358 PMID:32805266

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

decreases expression

enzalutamide results in decreased expression of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

cyclin B1

decreases expression

enzalutamide results in decreased expression of CCNB1 protein

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

CD46 molecule

increases expression

enzalutamide results in increased expression of CD46 protein

NCBI chr13:106,575,586...106,606,325
Ensembl chr13:106,574,858...106,660,445

G

cell division cycle 25C

multiple interactions

[enzalutamide co-treated with NVP-BHG712] results in decreased expression of CDC25C mRNA; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of CDC25C protein

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

cyclin-dependent kinase inhibitor 1B

affects expression

enzalutamide affects the expression of CDKN1B mRNA

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

CCAAT/enhancer binding protein alpha

affects expression

enzalutamide affects the expression of CEBPA mRNA

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CREB binding protein

affects expression

enzalutamide affects the expression of CREBBP mRNA

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

cysteine-rich secretory protein 3

decreases expression

enzalutamide results in decreased expression of CRISP3 mRNA

NCBI chr 9:20,432,051...20,472,663
Ensembl chr 9:20,450,908...20,472,658

G

crystallin, mu

multiple interactions
decreases expression

KDM1A protein promotes the reaction [enzalutamide results in decreased expression of CRYM mRNA]

NCBI chr 1:174,560,423...174,575,660
Ensembl chr 1:174,560,416...174,575,633

G

chondroitin sulfate N-acetylgalactosaminyltransferase 1

decreases expression

enzalutamide results in decreased expression of CSGALNACT1 mRNA

NCBI chr16:20,995,210...21,330,586
Ensembl chr16:21,235,784...21,330,319

G

dipeptidylpeptidase 4

decreases expression

enzalutamide results in decreased expression of DPP4 mRNA

NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901

G

deltex E3 ubiquitin ligase 2

affects expression

enzalutamide affects the expression of DTX2 mRNA

NCBI chr12:20,643,289...20,682,908
Ensembl chr12:20,643,297...20,682,885

G

deltex E3 ubiquitin ligase 3

affects expression

enzalutamide affects the expression of DTX3 mRNA

NCBI chr 7:63,013,769...63,018,431
Ensembl chr 7:63,013,371...63,018,522

G

deltex E3 ubiquitin ligase 4

affects expression

enzalutamide affects the expression of DTX4 mRNA

NCBI chr 1:209,457,719...209,545,163
Ensembl chr 1:209,460,735...209,492,818

G

ER degradation enhancing alpha-mannosidase like protein 3

decreases expression

enzalutamide results in decreased expression of EDEM3 mRNA

NCBI chr13:63,858,282...63,920,538
Ensembl chr13:63,858,716...63,920,523

G

embryonic ectoderm development

multiple interactions
decreases expression

[enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]]; enzalutamide promotes the reaction [GSK-2816126 results in decreased expression of EED protein]; GSK-2816126 promotes the reaction [enzalutamide results in decreased expression of EED protein]

NCBI chr 1:143,867,875...143,895,008
Ensembl chr 1:143,867,875...143,894,974

G

EF-hand calcium binding domain 12

decreases expression

enzalutamide results in decreased expression of EFCAB12 mRNA

NCBI chr 4:148,869,381...148,892,922
Ensembl chr 4:148,869,387...148,890,560

G

elongation factor for RNA polymerase II 2

decreases expression

enzalutamide results in decreased expression of ELL2 mRNA

NCBI chr 2:5,189,375...5,258,781
Ensembl chr 2:5,189,971...5,258,781

G

ELOVL fatty acid elongase 7

decreases expression

enzalutamide results in decreased expression of ELOVL7 mRNA

NCBI chr 2:39,789,229...39,858,579
Ensembl chr 2:39,789,250...39,856,845

G

E1A binding protein p300

affects expression

enzalutamide affects the expression of EP300 mRNA

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

EPH receptor B4

affects response to substance
multiple interactions

EPHB4 protein affects the susceptibility to enzalutamide
enzalutamide promotes the reaction [EPHB4 protein affects the expression of KLK3 protein]; EPHB4 protein affects the reaction [enzalutamide results in decreased cleavage of PARP1 protein]

NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314

G

Epsin 1

affects expression

enzalutamide affects the expression of EPN1 mRNA

NCBI chr 1:68,742,491...68,760,570
Ensembl chr 1:68,742,789...68,758,874

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

decreases expression
multiple interactions

enzalutamide results in decreased expression of EZH2 protein
[enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]]

NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362

G

FKBP prolyl isomerase 5

multiple interactions
decreases expression

[enzalutamide co-treated with NVP-BHG712] results in decreased expression of FKBP5 mRNA; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of FKBP5 mRNA]; NVP-BHG712 promotes the reaction [enzalutamide results in decreased expression of FKBP5 mRNA]

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

forkhead box A1

affects expression

enzalutamide affects the expression of FOXA1 mRNA

NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188

G

polypeptide N-acetylgalactosaminyltransferase 11

affects expression

enzalutamide affects the expression of GALNT11 mRNA

NCBI chr 4:9,837,629...9,871,141
Ensembl chr 4:9,837,629...9,871,140

G

GDP-mannose 4, 6-dehydratase

affects expression

enzalutamide affects the expression of GMDS mRNA

NCBI chr17:32,095,315...32,621,975
Ensembl chr17:32,095,386...32,621,961

G

glycine N-methyltransferase

decreases expression

enzalutamide results in decreased expression of GNMT mRNA

NCBI chr 9:14,254,675...14,258,028
Ensembl chr 9:14,254,675...14,258,434

G

glutamic-oxaloacetic transaminase 1

affects expression

enzalutamide affects the expression of GOT1 mRNA

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

growth regulating estrogen receptor binding 1

decreases expression

enzalutamide results in decreased expression of GREB1 mRNA

NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633

G

hes family bHLH transcription factor 1

affects expression

enzalutamide affects the expression of HES1 mRNA

NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192

G

HNF1 homeobox B

affects expression

enzalutamide affects the expression of HNF1B mRNA

NCBI chr10:68,735,894...68,789,888
Ensembl chr10:68,735,894...68,789,888

G

intraflagellar transport 172

affects expression

enzalutamide affects the expression of IFT172 mRNA

NCBI chr 6:25,081,933...25,121,271
Ensembl chr 6:25,081,980...25,120,860

G

intraflagellar transport 74

affects expression

enzalutamide affects the expression of IFT74 mRNA

NCBI chr 5:109,460,372...109,563,839
Ensembl chr 5:109,474,255...109,563,833

G

insulin-like growth factor 1

decreases expression

enzalutamide results in decreased expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 1 receptor

decreases expression

enzalutamide results in decreased expression of IGF1R mRNA

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

interleukin 6

multiple interactions
decreases response to substance

Niclosamide inhibits the reaction [IL6 protein results in decreased susceptibility to enzalutamide]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

IQ motif containing GTPase activating protein 2

decreases expression

enzalutamide results in decreased expression of IQGAP2 mRNA

NCBI chr 2:26,894,836...27,170,270
Ensembl chr 2:26,894,825...27,170,279

G

itchy E3 ubiquitin protein ligase

affects expression

enzalutamide affects the expression of ITCH mRNA

NCBI chr 3:143,642,348...143,733,745
Ensembl chr 3:143,645,637...143,733,543

G

integrin subunit beta 1 binding protein 1

affects expression

enzalutamide affects the expression of ITGB1BP1 mRNA

NCBI chr 6:40,820,693...40,836,074
Ensembl chr 6:40,821,339...40,836,037

G

jagged canonical Notch ligand 1

affects expression

enzalutamide affects the expression of JAG1 mRNA

NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209

G

jagged canonical Notch ligand 2

affects expression

enzalutamide affects the expression of JAG2 mRNA

NCBI chr 6:131,983,059...132,005,665
Ensembl chr 6:131,983,056...132,005,818

G

lysine acetyltransferase 2B

affects expression

enzalutamide affects the expression of KAT2B mRNA

NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064

G

lysine demethylase 1A

multiple interactions

KDM1A protein promotes the reaction [enzalutamide results in decreased expression of CRYM mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of KLK3 protein]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of LCP1 mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MAP2 mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MYO1B mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of SLC22A3 mRNA]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of TMCC3 mRNA]

NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319

G

kinesin family member 5C

decreases expression

enzalutamide results in decreased expression of KIF5C mRNA

NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413

G

kallikrein 1-related peptidase C10

increases expression
decreases expression
multiple interactions

enzalutamide results in increased expression of KLK3 mRNA
enzalutamide results in decreased expression of KLK3 mRNA; enzalutamide results in decreased expression of KLK3 protein
[enzalutamide co-treated with NVP-BHG712] results in decreased expression of KLK3 mRNA; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of KLK3 protein; [nirogacestat results in increased susceptibility to enzalutamide] which results in decreased expression of KLK3 protein; enzalutamide promotes the reaction [EPHB4 protein affects the expression of KLK3 protein]; enzalutamide promotes the reaction [Niclosamide results in decreased expression of KLK3 protein]; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of KLK3 mRNA]; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of KLK3 protein]; KDM1A protein promotes the reaction [enzalutamide results in decreased expression of KLK3 protein]; NVP-BHG712 promotes the reaction [enzalutamide results in decreased expression of KLK3 protein]

PMID:19359544 PMID:23704919 PMID:25970160 PMID:29581250 PMID:30940724 More...

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

keratin 19

affects expression

enzalutamide affects the expression of KRT19 mRNA

NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799

G

LCK proto-oncogene, Src family tyrosine kinase

decreases expression

enzalutamide results in decreased expression of LCK mRNA

NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794

G

lymphocyte cytosolic protein 1

multiple interactions
decreases expression

KDM1A protein promotes the reaction [enzalutamide results in decreased expression of LCP1 mRNA]

NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680

G

MAF bZIP transcription factor

decreases expression

enzalutamide results in decreased expression of MAF mRNA

NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365

G

mastermind-like transcriptional coactivator 1

affects expression

enzalutamide affects the expression of MAML1 mRNA

NCBI chr10:34,588,639...34,623,024
Ensembl chr10:34,588,646...34,623,338

G

mastermind-like transcriptional coactivator 3

affects expression

enzalutamide affects the expression of MAML3 mRNA

NCBI chr 2:135,720,431...136,137,829
Ensembl chr 2:135,721,021...136,137,814

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

[enzalutamide co-treated with GSK-2816126] results in increased expression of MAP1LC3B protein modified form

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

microtubule-associated protein 2

multiple interactions
decreases expression

KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MAP2 mRNA]

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

midkine

affects expression

enzalutamide affects the expression of MDK mRNA

NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130

G

MIB E3 ubiquitin protein ligase 1

affects expression

enzalutamide affects the expression of MIB1 mRNA

NCBI chr18:1,802,519...1,926,988
Ensembl chr18:1,802,519...1,920,689

G

MIB E3 ubiquitin protein ligase 2

affects expression

enzalutamide affects the expression of MIB2 mRNA

NCBI chr 5:166,243,776...166,259,944
Ensembl chr 5:166,243,776...166,259,650

G

marker of proliferation Ki-67

multiple interactions

enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of MKI67 protein]

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

mitochondrial pyruvate carrier 2

decreases expression

enzalutamide results in decreased expression of BRP44 mRNA

NCBI chr13:77,728,176...77,747,664
Ensembl chr13:77,728,250...77,747,664

G

microseminoprotein, beta

decreases expression

enzalutamide results in decreased expression of MSMB mRNA

NCBI chr16:7,366,536...7,387,124
Ensembl chr16:7,366,536...7,387,123

G

MYC proto-oncogene, bHLH transcription factor

decreases expression
multiple interactions
affects expression

enzalutamide results in decreased expression of MYC protein
[enzalutamide co-treated with NVP-BHG712] results in decreased expression of MYC protein; enzalutamide inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to MYC enhancer]]; enzalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of MYC mRNA]; enzalutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of MYC protein]; enzalutamide promotes the reaction [Niclosamide results in decreased expression of MYC protein]; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of MYC protein]
enzalutamide affects the expression of MYC mRNA

PMID:24759320 PMID:25970160 PMID:30940724 PMID:32184358

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

myosin Ib

multiple interactions
decreases expression

KDM1A protein promotes the reaction [enzalutamide results in decreased expression of MYO1B mRNA]

NCBI chr 9:49,690,043...49,852,373
Ensembl chr 9:49,690,086...49,850,798

G

nicastrin

affects expression

enzalutamide affects the expression of NCSTN mRNA

NCBI chr13:84,530,442...84,546,454
Ensembl chr13:84,530,440...84,546,454

G

neuralized E3 ubiquitin protein ligase 1B

affects expression

enzalutamide affects the expression of NEURL1B mRNA

NCBI chr10:16,754,002...16,785,049
Ensembl chr10:16,757,208...16,785,119

G

NFKB activating protein

affects expression

enzalutamide affects the expression of NKAP mRNA

NCBI chr X:116,373,031...116,392,677
Ensembl chr X:116,372,839...116,394,945

G

NK3 homeobox 1

decreases expression
multiple interactions

enzalutamide results in decreased expression of NKX3-1 mRNA
enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of NKX3-1 mRNA]; NVP-BHG712 promotes the reaction [enzalutamide results in decreased expression of NKX3-1 mRNA]

PMID:29581250 PMID:32184358

NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441

G

notchless homolog 1

affects expression

enzalutamide affects the expression of NLE1 mRNA

NCBI chr10:67,834,059...67,844,771
Ensembl chr10:67,834,062...67,842,658

G

notch receptor 1

affects response to substance
affects expression
multiple interactions

NOTCH1 protein affects the susceptibility to enzalutamide
enzalutamide affects the expression of NOTCH1 mRNA
[NOTCH1 protein affects the susceptibility to enzalutamide] which affects the cleavage of PARP1 protein

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

notch receptor 2

affects expression

enzalutamide affects the expression of NOTCH2 mRNA

NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088

G

notch receptor 3

affects expression

enzalutamide affects the expression of NOTCH3 mRNA

NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025

G

poly (ADP-ribose) polymerase 1

decreases cleavage
multiple interactions

enzalutamide results in decreased cleavage of PARP1 protein
[enzalutamide co-treated with GSK-2816126] results in increased cleavage of PARP1 protein; [nirogacestat results in increased susceptibility to enzalutamide] which results in increased cleavage of PARP1 protein; [NOTCH1 protein affects the susceptibility to enzalutamide] which affects the cleavage of PARP1 protein; enzalutamide promotes the reaction [NVP-BHG712 results in increased cleavage of PARP1 protein]; EPHB4 protein affects the reaction [enzalutamide results in decreased cleavage of PARP1 protein]

PMID:30940724 PMID:32184358 PMID:32805266

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

p53 apoptosis effector related to PMP22

affects expression

enzalutamide affects the expression of PERP mRNA

NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511

G

phospholipase A2, group V

decreases expression

enzalutamide results in decreased expression of PLA2G5 mRNA

NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658

G

polo-like kinase 1

multiple interactions

[enzalutamide co-treated with NVP-BHG712] results in decreased expression of PLK1 mRNA; [enzalutamide co-treated with NVP-BHG712] results in decreased expression of PLK1 protein; enzalutamide promotes the reaction [NVP-BHG712 results in decreased expression of PLK1 mRNA]

NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

decreases expression

enzalutamide results in decreased expression of PLOD2 mRNA

NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255

G

protein O-fucosyltransferase 1

affects expression

enzalutamide affects the expression of POFUT1 mRNA

NCBI chr 3:141,708,618...141,735,558
Ensembl chr 3:141,708,644...141,734,786

G

presenilin 1

affects expression

enzalutamide affects the expression of PSEN1 mRNA

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

presenilin 2

affects expression

enzalutamide affects the expression of PSEN2 mRNA

NCBI chr13:91,967,506...91,993,240
Ensembl chr13:91,967,983...91,993,174

G

presenilin enhancer gamma secretase subunit

affects expression

enzalutamide affects the expression of PSENEN mRNA

NCBI chr 1:85,814,905...85,816,654
Ensembl chr 1:85,814,905...85,816,192

G

prostaglandin E receptor 4

decreases expression

enzalutamide results in decreased expression of PTGER4 mRNA

NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670

G

RNA binding motif protein 15

affects expression

enzalutamide affects the expression of RBM15 mRNA

NCBI chr 2:194,945,974...194,954,498
Ensembl chr 2:194,945,974...194,954,703

G

recombination signal binding protein for immunoglobulin kappa J region

affects expression

enzalutamide affects the expression of RBPJ mRNA

NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353

G

regulator of G-protein signaling 2

decreases expression

enzalutamide results in decreased expression of RGS2 mRNA

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

ras homolog family member U

decreases expression

enzalutamide results in decreased expression of RHOU mRNA

NCBI chr19:51,641,476...51,651,249
Ensembl chr19:51,641,227...51,650,552

G

ribosomal protein S19

affects expression

enzalutamide affects the expression of RPS19 mRNA

NCBI chr 1:80,480,718...80,486,511
Ensembl chr 1:80,480,951...80,486,508

G

ribosomal protein S27a

affects expression

enzalutamide affects the expression of RPS27A mRNA

NCBI chr14:103,285,734...103,288,011
Ensembl chr14:103,285,734...103,288,011
Ensembl chr 5:103,285,734...103,288,011

G

sphingosine-1-phosphate receptor 3

affects expression

enzalutamide affects the expression of S1PR3 mRNA

NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505

G

SEL1L adaptor subunit of SYVN1 ubiquitin ligase

affects expression

enzalutamide affects the expression of SEL1L mRNA

NCBI chr 6:110,735,450...110,779,695
Ensembl chr 6:110,735,450...110,779,648

G

selenoprotein P

decreases expression

enzalutamide results in decreased expression of SELENOP mRNA

NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852

G

solute carrier family 22 member 3

multiple interactions
decreases expression

KDM1A protein promotes the reaction [enzalutamide results in decreased expression of SLC22A3 mRNA]

NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612

G

SNW domain containing 1

affects expression

enzalutamide affects the expression of SNW1 mRNA

NCBI chr 6:107,095,450...107,119,536
Ensembl chr 6:107,095,457...107,119,536

G

suppressor of cytokine signaling 2

decreases expression

enzalutamide results in decreased expression of SOCS2 mRNA

NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548

G

SRY-box transcription factor 9

affects expression

enzalutamide affects the expression of SOX9 mRNA

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

spen family transcriptional repressor

affects expression

enzalutamide affects the expression of SPEN mRNA

NCBI chr 5:153,775,287...153,848,677
Ensembl chr 5:153,776,234...153,848,811

G

sparc/osteonectin, cwcv and kazal like domains proteoglycan 1

decreases expression

enzalutamide results in decreased expression of SPOCK1 mRNA

NCBI chr17:6,741,504...7,221,685
Ensembl chr17:6,742,273...7,224,935

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1

decreases expression

enzalutamide results in decreased expression of ST6GALNAC1 mRNA

NCBI chr10:101,972,656...101,983,053
Ensembl chr10:101,972,668...101,983,053

G

signal transducer and activator of transcription 3

multiple interactions
decreases response to substance

enzalutamide promotes the reaction [Niclosamide results in decreased phosphorylation of and results in decreased activity of STAT3 protein]; Niclosamide inhibits the reaction [STAT3 protein results in decreased susceptibility to enzalutamide]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

sushi domain containing 5

affects expression

enzalutamide affects the expression of SUSD5 mRNA

NCBI chr 8:113,996,771...114,036,133
Ensembl chr 8:113,997,362...114,035,861

G

SUZ12 polycomb repressive complex 2 subunit

multiple interactions
decreases expression

[enzalutamide co-treated with GSK-2816126] inhibits the reaction [AR protein binds to [EZH2 protein binds to SUZ12 protein binds to EED protein]]; enzalutamide promotes the reaction [GSK-2816126 results in decreased expression of SUZ12 protein]; GSK-2816126 promotes the reaction [enzalutamide results in decreased expression of SUZ12 protein]

NCBI chr10:64,967,035...65,012,916
Ensembl chr10:64,966,967...65,012,738

G

teneurin transmembrane protein 1

decreases expression

enzalutamide results in decreased expression of TENM1 mRNA

NCBI chr X:121,400,466...122,289,877
Ensembl chr X:121,403,649...122,290,207

G

transmembrane and coiled-coil domain family 3

decreases expression
multiple interactions

enzalutamide results in decreased expression of TMCC3 mRNA
KDM1A protein promotes the reaction [enzalutamide results in decreased expression of TMCC3 mRNA]

NCBI chr 7:28,893,972...29,171,935
Ensembl chr 7:28,893,967...29,171,926

G

tumor protein D52

decreases expression

enzalutamide results in decreased expression of TPD52 mRNA

NCBI chr 2:92,735,365...92,816,079
Ensembl chr 2:92,735,620...92,816,622

G

transient receptor potential cation channel, subfamily M, member 8

decreases expression

enzalutamide results in decreased expression of TRPM8 mRNA

NCBI chr 9:88,897,039...88,990,167
Ensembl chr 9:88,903,880...88,988,552

G

ubiquitin A-52 residue ribosomal protein fusion product 1

affects expression

enzalutamide affects the expression of UBA52 mRNA

NCBI chr16:18,918,614...18,920,807
Ensembl chr16:18,900,616...18,920,807

G

ubiquitin B

affects expression

enzalutamide affects the expression of UBB mRNA

NCBI chr10:47,247,630...47,249,335
Ensembl chr10:47,245,637...47,249,333

G

ubiquitin C

affects expression

enzalutamide affects the expression of UBC mRNA

NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925

G

ubiquitin-conjugating enzyme E2C

multiple interactions

[enzalutamide co-treated with NVP-BHG712] results in decreased expression of UBE2C mRNA

NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339

G

WD repeat domain 12

affects expression

enzalutamide affects the expression of WDR12 mRNA

NCBI chr 9:61,475,498...61,502,762
Ensembl chr 9:61,475,517...61,502,469

G

WW domain containing transcription regulator 1

decreases expression

enzalutamide results in decreased expression of WWTR1 mRNA

NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968

ethotoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

ethotoin binds to and results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

Ethylenethiourea

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases expression
decreases activity

Ethylenethiourea results in decreased expression of ACHE protein
Ethylenethiourea results in decreased activity of ACHE protein

PMID:3868355 PMID:21251949

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

actin-like 7a

decreases expression

Ethylenethiourea results in decreased expression of ACTL7A mRNA

NCBI chr 5:71,447,447...71,450,440
Ensembl chr 5:71,447,071...71,450,908

G

anti-Mullerian hormone

decreases expression

Ethylenethiourea results in decreased expression of AMH protein

NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282

G

ATPase Na+/K+ transporting subunit alpha 2

decreases expression

Ethylenethiourea results in decreased expression of ATP1A2 mRNA

NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of BCL2 mRNA
[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

brain expressed X-linked 1

multiple interactions
decreases expression

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of BEX2 mRNA
Ethylenethiourea results in decreased expression of BEX2 mRNA

NCBI chr X:99,219,014...99,220,518
Ensembl chr X:99,219,014...99,220,958

G

bone morphogenetic protein 4

decreases expression

Ethylenethiourea results in decreased expression of BMP4 mRNA

PMID:17161201 PMID:18082712

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions
decreases expression
increases expression

Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of CYP19A1 mRNA]
Ethylenethiourea results in decreased expression of CYP19A1 mRNA; Ethylenethiourea results in decreased expression of CYP19A1 protein
Ethylenethiourea results in increased expression of CYP19A1 mRNA

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

DNA-damage-inducible transcript 4

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of DDIT4 mRNA
[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of DDIT4 mRNA

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

iodothyronine deiodinase 1

decreases expression

Ethylenethiourea results in decreased expression of DIO1 mRNA

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

iodothyronine deiodinase 2

decreases expression
multiple interactions
affects expression

Ethylenethiourea results in decreased expression of DIO2 mRNA
[Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of DIO2 mRNA
Ethylenethiourea affects the expression of DIO2 mRNA

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

iodothyronine deiodinase 3

increases expression
affects expression
decreases expression
multiple interactions

Ethylenethiourea results in increased expression of DIO3 mRNA
Ethylenethiourea affects the expression of DIO3 protein
Ethylenethiourea results in decreased expression of DIO3 mRNA
Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of DIO3 mRNA]

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

early growth response 1

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of EGR1 mRNA
[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

endoplasmic reticulum-golgi intermediate compartment 1

decreases expression

Ethylenethiourea results in decreased expression of ERGIC1 mRNA

NCBI chr10:16,531,192...16,626,974
Ensembl chr10:16,531,194...16,626,957

G

estrogen receptor 1

multiple interactions

Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of ESR1 mRNA]

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

flavin containing dimethylaniline monoxygenase 2

decreases oxidation
increases oxidation

FMO2 gene polymorphism results in decreased oxidation of Ethylenethiourea
FMO2 protein results in increased oxidation of Ethylenethiourea

NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308

G

fascin actin-bundling protein 2, retinal

multiple interactions
decreases expression

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of FSCN2 mRNA
Ethylenethiourea results in decreased expression of FSCN2 mRNA

NCBI chr10:105,634,783...105,641,322
Ensembl chr10:105,634,783...105,641,322

G

Fus RNA binding protein

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of FUS mRNA
[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of FUS mRNA

NCBI chr 1:182,576,479...182,590,417
Ensembl chr 1:182,576,545...182,590,414

G

frizzled class receptor 5

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of FZD5 mRNA
[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of FZD5 mRNA

NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457

G

gap junction protein, alpha 1

multiple interactions
increases expression

[Triiodothyronine co-treated with Ethylenethiourea] results in increased expression of GJA1 mRNA
Ethylenethiourea results in increased expression of GJA1 mRNA

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

G protein subunit alpha o1

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of GNAO1 mRNA

NCBI chr19:11,034,874...11,192,531
Ensembl chr19:11,035,956...11,192,493

G

general transcription factor 3C subunit 6

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of GTF3C6 mRNA

NCBI chr20:43,656,400...43,668,382
Ensembl chr20:43,655,875...43,667,873

G

H2A.X variant histone

increases phosphorylation

Ethylenethiourea results in increased phosphorylation of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

H2B.U histone 1

decreases expression

Ethylenethiourea results in decreased expression of H2BU1 mRNA

NCBI chr10:43,732,737...43,733,484
Ensembl chr10:43,732,864...43,736,277

G

HEXIM P-TEFb complex subunit 2

decreases expression

Ethylenethiourea results in decreased expression of HEXIM2 mRNA

NCBI chr10:88,077,870...88,084,776
Ensembl chr10:88,079,014...88,084,775

G

high mobility group AT-hook 1

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of HMGA1 mRNA
[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of HMGA1 mRNA

NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752

G

homeo box A13

decreases expression

Ethylenethiourea results in decreased expression of HOXA13 mRNA

PMID:17161201 PMID:18082712

NCBI chr 4:81,358,956...81,361,091
Ensembl chr 4:81,358,956...81,361,091

G

homeo box D13

decreases expression

Ethylenethiourea results in decreased expression of HOXD13 mRNA

PMID:17161201 PMID:18082712

NCBI chr 3:59,570,647...59,573,963
Ensembl chr 3:59,570,646...59,573,963

G

interferon-induced protein with tetratricopeptide repeats 3

decreases expression

Ethylenethiourea results in decreased expression of IFIT3 mRNA

NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307

G

interleukin 1 beta

multiple interactions

[aminomethylphosphonic acid (AMPA) co-treated with 2,4-Dichlorophenoxyacetic Acid metabolite co-treated with Ethylenethiourea co-treated with desethylatrazine] results in decreased expression of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

inhibin subunit alpha

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of INHA mRNA
[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of INHA mRNA

NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248

G

inositol polyphosphate-5-phosphatase J

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of INPP5J mRNA

NCBI chr14:78,374,161...78,385,305
Ensembl chr14:78,374,161...78,385,326

G

jagged canonical Notch ligand 1

increases expression

Ethylenethiourea results in increased expression of JAG1 mRNA alternative form

NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209

G

marker of proliferation Ki-67

increases expression

Ethylenethiourea results in increased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

p21 (RAC1) activated kinase 2

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of PAK2 mRNA

NCBI chr11:68,707,940...68,768,816
Ensembl chr11:68,707,969...68,768,816

G

POM121 transmembrane nucleoporin-like 2

decreases expression

Ethylenethiourea results in decreased expression of POM121L2 mRNA

NCBI chr17:42,546,144...42,553,447
Ensembl chr17:42,546,326...42,553,423

G

POU class 5 homeobox 1

multiple interactions
decreases expression

Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of POU5F1 mRNA]
Ethylenethiourea results in decreased expression of POU5F1 mRNA

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

receptor accessory protein 6

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of REEP6 mRNA

NCBI chr 7:9,373,927...9,380,845
Ensembl chr 7:9,373,927...9,380,597

G

RUNX family transcription factor 2

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of RUNX2 mRNA

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

sonic hedgehog signaling molecule

decreases expression

Ethylenethiourea results in decreased expression of SHH mRNA

PMID:16369776 PMID:17161201 PMID:18082712

NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170

G

SRY-box transcription factor 9

increases expression
multiple interactions
decreases expression

Ethylenethiourea results in increased expression of SOX9 protein
[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of SOX9 mRNA
Ethylenethiourea results in decreased expression of SOX9 mRNA

PMID:34571837 PMID:35930101

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

steroidogenic acute regulatory protein

multiple interactions
decreases expression

[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of STAR mRNA
Ethylenethiourea results in decreased expression of STAR mRNA

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

stimulated by retinoic acid 8

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of STRA8 mRNA
[Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of STRA8 mRNA

NCBI chr 4:63,601,443...63,624,777
Ensembl chr 4:63,601,604...63,624,771

G

synaptonemal complex protein 1

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of SYCP1 mRNA
[Ethylenethiourea co-treated with Triiodothyronine] results in decreased expression of SYCP1 mRNA

NCBI chr 2:190,296,688...190,456,687
Ensembl chr 2:190,296,954...190,456,737

G

terminal nucleotidyltransferase 5D

decreases expression

Ethylenethiourea results in decreased expression of TENT5D mRNA

NCBI chr X:72,901,287...72,974,562
Ensembl chr X:72,901,241...72,970,573

G

thyroglobulin

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of TG mRNA
[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of TG mRNA

NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210

G

thyroid hormone receptor alpha

multiple interactions
decreases expression

[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of THRA mRNA
Ethylenethiourea results in decreased expression of THRA mRNA

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

thyroid hormone receptor beta

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of THRB mRNA
Ethylenethiourea inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

thyroid hormone responsive

decreases expression
multiple interactions

Ethylenethiourea results in decreased expression of THRSP mRNA
[Ethylenethiourea co-treated with Triiodothyronine] results in increased expression of THRSP mRNA

NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075

G

thyroid peroxidase

decreases activity
affects activity

Ethylenethiourea results in decreased activity of TPO protein
Ethylenethiourea affects the activity of TPO protein

PMID:7626075 PMID:9248629 PMID:31629072

NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199

G

Wnt family member 4

multiple interactions
decreases expression

[Triiodothyronine co-treated with Ethylenethiourea] results in decreased expression of WNT4 mRNA
Ethylenethiourea results in decreased expression of WNT4 mRNA

NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859

G

zinc finger protein 362

multiple interactions

[Chlorpyrifos co-treated with Ethylenethiourea] results in decreased expression of ZFP362 mRNA

NCBI chr 5:141,119,073...141,153,304
Ensembl chr 5:141,119,898...141,156,716

G

zinc finger protein 36, C3H type-like 2

decreases expression

Ethylenethiourea results in decreased expression of ZFP36L2 mRNA

NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064

G

zinc finger protein 524

decreases expression

Ethylenethiourea results in decreased expression of ZFP524 mRNA

NCBI chr 1:68,824,803...68,828,363
Ensembl chr 1:68,824,803...68,828,594

G

zinc finger protein 703

decreases expression

Ethylenethiourea results in decreased expression of ZFP703 mRNA

NCBI chr16:65,076,507...65,080,677
Ensembl chr16:65,076,507...65,080,677

Hydroxymephenytoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases chemical synthesis
multiple interactions

CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin
[CYP2C19 protein results in increased hydroxylation of Mephenytoin] which results in increased chemical synthesis of 4-hydroxymephenytoin; [CYP2C19 protein results in increased metabolism of Mephenytoin] which results in increased chemical synthesis of 4-hydroxymephenytoin; Fluoxetine inhibits the reaction [CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin]

PMID:12401345 PMID:15155557 PMID:21915887 PMID:23850985 PMID:25084468 More...

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

imidacloprid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RIKEN cDNA 1700012B07 gene like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of 1700012B07RKL gene

NCBI chr10:94,771,471...94,804,839
Ensembl chr10:94,771,554...94,804,839

G

acetylcholinesterase

increases activity
increases expression

imidacloprid results in increased activity of ACHE protein
imidacloprid results in increased expression of ACHE protein

PMID:18080902 PMID:26024013 PMID:37648049

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

acyl-CoA thioesterase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ACOT2 gene

NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245

G

acyl-CoA thioesterase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACOT4 mRNA

NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917

G

aminoacylase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACY1 mRNA

NCBI chr 8:107,072,354...107,077,756
Ensembl chr 8:107,072,358...107,077,682

G

ADAM metallopeptidase domain 15

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAM15 gene

NCBI chr 2:174,754,629...174,765,136
Ensembl chr 2:174,754,633...174,765,113

G

ADAMTS-like 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAMTSL3 gene

NCBI chr 1:136,288,793...136,596,986
Ensembl chr 1:136,288,793...136,596,986

G

adenylate cyclase 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ADCY6 mRNA

NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754

G

ADRM1 26S proteasome ubiquitin receptor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ADRM1 mRNA

NCBI chr 3:167,265,435...167,270,197
Ensembl chr 3:167,265,296...167,270,195

G

alpha-fetoprotein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AFP mRNA

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

angiotensinogen

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AGT mRNA

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aryl hydrocarbon receptor

affects expression

imidacloprid affects the expression of AHR mRNA

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

androgen-induced 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of AIG1 gene

NCBI chr 1:8,046,430...8,269,276
Ensembl chr 1:8,046,430...8,269,084

G

A-kinase anchoring protein 8

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8 mRNA

NCBI chr 7:11,316,224...11,332,523
Ensembl chr 7:11,316,228...11,332,399

G

A-kinase anchoring protein 8 like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8L mRNA

NCBI chr 7:11,332,671...11,362,287
Ensembl chr 7:11,332,672...11,362,275

G

albumin

multiple interactions
decreases expression

[imidacloprid co-treated with sodium arsenate] results in decreased expression of ALB protein
imidacloprid results in decreased expression of ALB protein

PMID:30033815 PMID:34993831

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 9 family, member A1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALDH9A1 mRNA

NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568

G

ALG2, alpha-1,3/1,6-mannosyltransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALG2 mRNA

NCBI chr 5:61,768,738...61,773,297
Ensembl chr 5:61,768,740...61,773,297

G

adenosine monophosphate deaminase 1

decreases expression

imidacloprid results in decreased expression of AMPD1 mRNA

NCBI chr 2:190,598,707...190,619,938
Ensembl chr 2:190,598,700...190,619,938

G

angiopoietin-like 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin repeat and sterile alpha motif domain containing 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ANKS3 mRNA

NCBI chr10:10,614,953...10,635,815
Ensembl chr10:10,615,047...10,635,806

G

annexin A11

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANXA11 mRNA

NCBI chr16:1,412,373...1,457,814
Ensembl chr16:1,410,756...1,457,797

G

APC regulator of WNT signaling pathway

affects methylation
multiple interactions

imidacloprid affects the methylation of APC promoter
LIF protein affects the reaction [imidacloprid affects the methylation of APC promoter]

NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696

G

aprataxin and PNKP like factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APLF mRNA

NCBI chr 4:120,070,471...120,122,656
Ensembl chr 4:120,070,471...120,122,633

G

apolipoprotein F

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APOF mRNA

NCBI chr 7:700,688...702,130
Ensembl chr 7:700,762...701,946

G

androgen receptor

decreases expression
affects expression

imidacloprid results in decreased expression of AR mRNA; imidacloprid results in decreased expression of AR protein
imidacloprid affects the expression of AR mRNA

PMID:31780179 PMID:35457321

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ADP-ribosylation factor 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ARF2 mRNA

NCBI chr10:88,867,836...88,889,654
Ensembl chr10:88,867,836...88,889,659

G

actin related protein 2/3 complex, subunit 1A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ARPC1A gene

NCBI chr12:9,502,496...9,525,304
Ensembl chr12:9,502,501...9,525,330

G

ankyrin repeat and SOCS box-containing 7

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ASB7 mRNA

NCBI chr 1:120,222,835...120,267,411
Ensembl chr 1:120,222,745...120,267,282

G

argininosuccinate synthase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ASS1 mRNA

NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903

G

atos homolog A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ATOSA mRNA

NCBI chr 8:75,694,828...75,772,565
Ensembl chr 8:75,695,022...75,772,549

G

ATP synthase membrane subunit c locus 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP5MC1 mRNA

NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124
Ensembl chr10:81,023,925...81,027,124

G

ATPase H+ transporting V0 subunit D1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP6V0D1 mRNA

NCBI chr19:33,403,352...33,447,357
Ensembl chr19:33,403,355...33,447,450

G

BAG cochaperone 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BAG3 mRNA

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

Btg3 associated nuclear protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BANP mRNA

NCBI chr19:50,007,710...50,082,742
Ensembl chr19:50,007,881...50,082,738

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

imidacloprid results in increased expression of BAX mRNA; imidacloprid results in increased expression of BAX protein
Thymol inhibits the reaction [imidacloprid results in increased expression of BAX mRNA]

PMID:27914857 PMID:34171690

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

butyrylcholinesterase

increases activity

imidacloprid results in increased activity of BCHE protein

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

imidacloprid results in decreased expression of BCL2 mRNA
Thymol inhibits the reaction [imidacloprid results in decreased expression of BCL2 mRNA]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL9, transcription coactivator

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of BCL9 mRNA

NCBI chr 2:184,760,616...184,846,261
Ensembl chr 2:184,760,618...184,786,435

G

betaine-homocysteine S-methyltransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BHMT mRNA

NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742

G

complement C1q C chain

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C1QC mRNA

NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017

G

similar to human chromosome 11 open reading frame 54

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C8H11ORF54 mRNA

NCBI chr 8:12,123,839...12,146,412
Ensembl chr 8:12,123,823...12,146,473

G

calcium voltage-gated channel subunit alpha1 H

increases expression

imidacloprid results in increased expression of CACNA1H mRNA

NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376

G

calcium voltage-gated channel auxiliary subunit gamma 1

decreases expression

imidacloprid results in decreased expression of CACNG1 mRNA

NCBI chr10:92,652,924...92,665,612
Ensembl chr10:92,652,614...92,665,783

G

calcium/calmodulin-dependent protein kinase II gamma

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAMK2G mRNA

NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050

G

calcium/calmodulin-dependent protein kinase kinase 2

decreases expression
multiple interactions

imidacloprid results in decreased expression of CAMKK2 protein
Dietary Fats promotes the reaction [imidacloprid results in decreased expression of CAMKK2 protein]

NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279

G

cyclase associated actin cytoskeleton regulatory protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CAP1 mRNA

NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769

G

calcyphosine 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAPS2 mRNA

NCBI chr 7:47,580,636...47,641,598
Ensembl chr 7:47,581,137...47,639,229

G

caspase 3

increases expression
multiple interactions

imidacloprid results in increased expression of CASP3 mRNA; imidacloprid results in increased expression of CASP3 protein
Thymol inhibits the reaction [imidacloprid results in increased expression of CASP3 mRNA]; Thymol inhibits the reaction [imidacloprid results in increased expression of CASP3 protein]

PMID:34171690 PMID:34993831 PMID:37648049

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

decreases activity
decreases expression
multiple interactions

imidacloprid results in decreased activity of CAT protein
imidacloprid results in decreased expression of CAT protein
imidacloprid promotes the reaction [sodium arsenate results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [imidacloprid results in decreased expression of CAT protein]; sodium arsenate promotes the reaction [imidacloprid results in decreased activity of CAT protein]; Thymol inhibits the reaction [imidacloprid results in decreased activity of CAT protein]

PMID:20686345 PMID:30033815 PMID:30456172 PMID:34171690 PMID:35398170

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cystathionine beta synthase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CBS mRNA

NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764

G

coiled-coil domain containing 125

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCDC125 mRNA

NCBI chr 2:31,809,120...31,835,538
Ensembl chr 2:31,809,228...31,850,152

G

coiled-coil domain containing 81

increases expression

imidacloprid results in increased expression of CCDC81 mRNA

NCBI chr 1:143,739,472...143,791,026
Ensembl chr 1:143,739,474...143,790,926

G

cyclin L1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCNL1 mRNA

NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368

G

CD36 molecule

increases expression

imidacloprid results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cadherin 1

multiple interactions
affects methylation

LIF protein affects the reaction [imidacloprid affects the methylation of CDH1 promoter]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2A

affects methylation
multiple interactions

imidacloprid affects the methylation of CDKN2A promoter
LIF protein affects the reaction [imidacloprid affects the methylation of CDKN2A promoter]

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

CCAAT/enhancer binding protein delta

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

CUGBP, Elav-like family member 6

increases expression

imidacloprid results in increased expression of CELF6 mRNA

NCBI chr 8:59,975,095...60,006,060
Ensembl chr 8:59,975,088...60,005,041

G

centrosomal protein 85

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CEP85 mRNA

NCBI chr 5:146,356,571...146,404,155
Ensembl chr 5:146,356,576...146,404,060

G

ceramide kinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CERK mRNA

NCBI chr 7:117,225,855...117,269,436
Ensembl chr 7:117,225,855...117,268,759

G

complement factor B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFB mRNA

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

cofilin 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFL1 mRNA

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

coiled-coil-helix-coiled-coil-helix domain containing 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CHCHD10 mRNA

NCBI chr20:12,725,839...12,727,638
Ensembl chr20:12,725,842...12,732,763

G

checkpoint kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CHEK2 mRNA

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

cholinergic receptor, muscarinic 1

increases expression

imidacloprid results in increased expression of CHRM1 mRNA

NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356

G

cholinergic receptor, muscarinic 2

increases expression

imidacloprid results in increased expression of CHRM2 protein

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

cholinergic receptor nicotinic alpha 1 subunit

multiple interactions

imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]; LYNX1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]; LYPD1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]

NCBI chr 3:58,454,763...58,469,832
Ensembl chr 3:58,454,744...58,469,840

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

imidacloprid results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]

NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions

imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; imidacloprid binds to [CHRNA4 protein co-treated with CHRNB2 protein]
imidacloprid inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB4 protein]

PMID:10377228 PMID:10728888 PMID:21538459 PMID:34628512

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic alpha 7 subunit

increases activity

imidacloprid metabolite results in increased activity of CHRNA7 protein; imidacloprid results in increased activity of CHRNA7 protein

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

[NACHRA8 protein co-treated with CHRNB2 protein] affects the susceptibility to imidacloprid; imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; imidacloprid binds to [CHRNA4 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRA1 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRA2 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRALPHA1 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRALPHA2 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRALPHA3 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]; imidacloprid results in increased activity of [NACHRA1 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [NACHRA1 protein co-treated with NACHRA2 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [NACHRA2 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [NACHRA8 protein co-treated with CHRNB2 protein]; LYNX1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]; LYPD1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]
imidacloprid inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]

PMID:10377228 PMID:10728888 PMID:16291090 PMID:16981889 PMID:18824080 More...

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

G

cholinergic receptor nicotinic beta 4 subunit

multiple interactions

imidacloprid results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB4 protein]

NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027

G

cold inducible RNA binding protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CIRBP mRNA

NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818

G

cardiotrophin-like cytokine factor 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CLCF1 mRNA

NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605

G

claudin 1

decreases expression

imidacloprid results in decreased expression of CLDN1 mRNA

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

clusterin

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CLU mRNA

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

carnosine dipeptidase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CNDP2 mRNA

NCBI chr18:78,039,924...78,057,030
Ensembl chr18:78,039,932...78,056,922

G

carnitine palmitoyltransferase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CPT2 mRNA

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

crumbs cell polarity complex component 3

increases expression

imidacloprid results in increased expression of CRB3 mRNA

NCBI chr 9:1,898,531...1,903,860
Ensembl chr 9:1,896,623...1,903,859

G

cryptochrome circadian regulator 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CRY1 mRNA

NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091

G

centrosome and spindle pole associated protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSPP1 mRNA

NCBI chr 5:9,077,161...9,192,402
Ensembl chr 5:9,077,161...9,193,377

G

cysteine and serine rich nuclear protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSRNP1 mRNA

NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183

G

cystathionine gamma-lyase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of CTH gene

NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234

G

catenin alpha-like 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CTNNAL1 mRNA

NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431

G

catenin delta 1

increases expression

imidacloprid results in increased expression of CTNND1 mRNA

NCBI chr 3:69,683,328...69,734,550
Ensembl chr 3:69,683,313...69,734,516

G

cut-like homeobox 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CUX2 mRNA

NCBI chr12:34,507,723...34,707,581
Ensembl chr12:34,520,959...34,705,806

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression
multiple interactions

imidacloprid results in decreased expression of CYP11A1 mRNA
Thymol inhibits the reaction [imidacloprid results in decreased expression of CYP11A1 mRNA]

PMID:31780179 PMID:34171690

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression
multiple interactions

imidacloprid results in decreased expression of CYP17A1 mRNA
Thymol inhibits the reaction [imidacloprid results in decreased expression of CYP17A1 mRNA]

PMID:27782041 PMID:31780179 PMID:34171690

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 19, subfamily a, polypeptide 1

increases activity
decreases expression
multiple interactions
affects expression

imidacloprid results in increased activity of CYP19A1 protein
imidacloprid results in decreased expression of CYP19A1 mRNA
Thymol inhibits the reaction [imidacloprid results in decreased expression of CYP19A1 mRNA]
imidacloprid affects the expression of CYP19A1 mRNA
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione affects the reaction [imidacloprid affects the expression of CYP19A1 mRNA]

PMID:28750898 PMID:29701941 PMID:34171690

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

imidacloprid results in increased expression of CYP2B10 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily c, polypeptide 22

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP2C22 mRNA

NCBI chr 1:238,991,698...239,031,323
Ensembl chr 1:238,991,610...239,021,738

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

imidacloprid results in increased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 4, subfamily a, polypeptide 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4A1 mRNA

NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464

G

cytochrome P450, family 4, subfamily f, polypeptide 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4F1 mRNA

NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046

G

cytochrome P450, family 4, subfamily f, polypeptide 18

increases expression

imidacloprid results in increased expression of CYP4F18 mRNA

NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940

G

cytohesin 1 interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CYTIP mRNA

NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993

G

D-box binding PAR bZIP transcription factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DBP mRNA

NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745

G

DNA cross-link repair 1C

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DCLRE1C mRNA

NCBI chr17:74,775,828...74,810,089
Ensembl chr17:74,776,935...74,809,186

G

DEAD-box helicase 20

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX20 mRNA

NCBI chr 2:193,158,761...193,168,484
Ensembl chr 2:193,158,823...193,166,774

G

DEAD-box helicase 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX5 mRNA

NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283

G

DNA fragmentation factor subunit beta

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DFFB mRNA

NCBI chr 5:164,522,446...164,534,733
Ensembl chr 5:164,522,463...164,534,628

G

discs large MAGUK scaffold protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DLG2 gene

NCBI chr 1:144,451,653...146,503,949
Ensembl chr 1:144,451,472...146,499,475

G

delta like canonical Notch ligand 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DLL1 mRNA

NCBI chr 1:56,312,062...56,320,177
Ensembl chr 1:56,312,066...56,320,179

G

doublesex and mab-3 related transcription factor 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DMRT3 gene

NCBI chr 1:223,244,340...223,264,254
Ensembl chr 1:223,248,747...223,262,530

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB1 mRNA

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

DnaJ heat shock protein family (Hsp40) member B9

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB9 mRNA

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

dipeptidylpeptidase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DPP4 mRNA

NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901

G

dual specificity phosphatase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DUSP5 gene

NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818

G

dual specificity phosphatase 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP6 mRNA

NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185

G

DAZ interacting zinc finger protein 1-like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DZIP1L gene

NCBI chr 8:100,188,414...100,229,077
Ensembl chr 8:100,194,999...100,228,988

G

elastin microfibril interfacer 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of EMILIN1 mRNA

NCBI chr 6:25,455,974...25,463,713
Ensembl chr 6:25,445,298...25,463,698

G

ectonucleotide pyrophosphatase/phosphodiesterase 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ENPP3 mRNA

NCBI chr 1:20,563,700...20,635,044
Ensembl chr 1:20,563,697...20,635,041

G

erythrocyte membrane protein band 4.1-like 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of EPB41L3 gene

NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607

G

EPM2A interacting protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of EPM2AIP1 mRNA

NCBI chr 8:111,233,871...111,241,219
Ensembl chr 8:111,233,826...111,241,871

G

Ets2 repressor factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ERF mRNA

NCBI chr 1:80,829,935...80,838,388
Ensembl chr 1:80,829,935...80,838,388

G

esterase D

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ESD mRNA

NCBI chr15:50,043,634...50,063,134
Ensembl chr15:50,043,632...50,063,144

G

estrogen receptor 1

increases expression

imidacloprid results in increased expression of ESR1 mRNA

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

affects expression

imidacloprid affects the expression of ESR2 mRNA

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

coagulation factor II (thrombin) receptor-like 2

increases expression

imidacloprid results in increased expression of F2RL2 mRNA

NCBI chr 2:26,972,054...26,977,098
Ensembl chr 2:26,972,054...26,977,098

G

family with sequence similarity 135, member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM135A mRNA

NCBI chr 9:26,420,116...26,500,803
Ensembl chr 9:26,420,528...26,500,717

G

family with sequence similarity 177, member A1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM177A1 gene

NCBI chr 6:72,632,628...72,647,553
Ensembl chr 6:72,632,623...72,647,553

G

family with sequence similarity 204, member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM204A mRNA

NCBI chr 1:259,328,551...259,366,726
Ensembl chr 1:259,337,709...259,367,077

G

family with sequence similarity 53, member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM53A gene

NCBI chr14:77,088,178...77,124,395
Ensembl chr14:77,090,723...77,124,395

G

FIC domain protein adenylyltransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FICD mRNA

NCBI chr12:42,889,195...42,894,090
Ensembl chr12:42,889,194...42,894,070

G

FKBP prolyl isomerase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FKBP4 mRNA

NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833

G

FKBP prolyl isomerase 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of FKBP5 gene

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

formin 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FMN1 mRNA

NCBI chr 3:100,101,103...100,485,652
Ensembl chr 3:100,134,549...100,479,220

G

FERM domain containing 4B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FRMD4B mRNA

NCBI chr 4:129,895,401...130,222,070
Ensembl chr 4:129,895,708...130,084,197

G

follicle stimulating hormone subunit beta

multiple interactions
increases expression

Thymol inhibits the reaction [imidacloprid results in increased expression of FSHB protein]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

frizzled class receptor 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FZD6 mRNA

NCBI chr 7:70,055,012...70,086,781
Ensembl chr 7:70,055,068...70,086,776

G

growth arrest and DNA-damage-inducible, gamma

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GADD45G mRNA

NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610

G

polypeptide N-acetylgalactosaminyltransferase 7

increases expression

imidacloprid results in increased expression of GALNT7 mRNA

NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690

G

glutamine amidotransferase class 1 domain containing 3A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GATD3A mRNA

NCBI chr20:10,514,793...10,522,894
Ensembl chr20:10,514,744...10,522,885

G

growth differentiation factor 15

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

glial fibrillary acidic protein

increases expression

imidacloprid results in increased expression of GFAP protein

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

gypsy retrotransposon integrase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIN1 mRNA

NCBI chr 9:98,293,596...98,315,155
Ensembl chr 9:98,293,597...98,315,848

G

GIT ArfGAP 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIT2 mRNA

NCBI chr12:41,829,717...41,872,621
Ensembl chr12:41,829,730...41,871,097

G

gap junction protein, alpha 1

decreases expression

imidacloprid results in decreased expression of GJA1 mRNA

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

galactosidase, beta 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GLB1 mRNA

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

glucosamine-6-phosphate deaminase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GNPDA2 mRNA

NCBI chr14:38,520,663...38,538,713
Ensembl chr14:38,520,705...38,538,713

G

G protein-coupled receptor associated sorting protein family member 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GPRASP3 mRNA

NCBI chr X:98,847,591...98,854,949
Ensembl chr X:98,817,593...98,854,545

G

glutamic--pyruvic transaminase

increases activity
increases expression
multiple interactions

imidacloprid results in increased activity of GPT protein
imidacloprid results in increased expression of GPT protein
[imidacloprid co-treated with fipronil co-treated with Glyphosate] results in increased activity of and results in increased secretion of GPT protein
[imidacloprid co-treated with sodium arsenate] results in increased activity of GPT protein

PMID:30033815 PMID:34993831 PMID:35850439

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

GRAM domain containing 1A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GRAMD1A mRNA

NCBI chr 1:86,367,001...86,393,348
Ensembl chr 1:86,367,001...86,393,336

G

glutamate ionotropic receptor AMPA type subunit 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GRIA1 gene

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor NMDA type subunit associated protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GRINA mRNA

NCBI chr 7:107,962,194...107,965,372
Ensembl chr 7:107,962,207...107,965,366

G

gasdermin A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GSDMA gene

NCBI chr10:83,614,336...83,639,543
Ensembl chr10:83,627,051...83,639,543

G

glutathione-disulfide reductase

multiple interactions
decreases activity

imidacloprid promotes the reaction [sodium arsenate results in decreased activity of GSR protein]; sodium arsenate promotes the reaction [imidacloprid results in decreased activity of GSR protein]

PMID:30033815 PMID:30456172

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase kappa 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GSTK1 mRNA

NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292

G

hydroxyacid oxidase 1

decreases expression

imidacloprid results in decreased expression of HAO1 mRNA

NCBI chr 3:121,757,400...121,828,721
Ensembl chr 3:121,771,836...121,828,721

G

HUWE1 associated protein modifying stress responses 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of HAPSTR2 gene

NCBI chr X:138,922,089...138,924,124
Ensembl chr X:138,922,100...138,922,918

G

histidyl-tRNA synthetase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HARS1 mRNA

NCBI chr18:28,381,649...28,398,699
Ensembl chr18:28,381,655...28,398,740

G

heme binding protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HEBP1 mRNA

NCBI chr 4:167,974,316...168,003,854
Ensembl chr 4:167,974,319...168,003,854

G

hes family bHLH transcription factor 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HES1 mRNA

NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192

G

hemojuvelin BMP co-receptor

decreases expression

imidacloprid results in decreased expression of HJV mRNA

NCBI chr 2:184,065,944...184,069,851
Ensembl chr 2:184,065,970...184,069,850

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases expression

imidacloprid results in decreased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

heme oxygenase 1

increases expression

imidacloprid results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heparan sulfate-glucosamine 3-sulfotransferase 3B1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HS3ST3B1 mRNA

NCBI chr10:48,561,473...48,593,970
Ensembl chr10:48,561,473...48,593,970

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD11B2 mRNA

NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899

G

hydroxysteroid (17-beta) dehydrogenase 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD17B10 mRNA

NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488

G

hydroxysteroid (17-beta) dehydrogenase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HSD17B2 mRNA

NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202

G

hydroxysteroid (17-beta) dehydrogenase 3

multiple interactions
decreases expression

Thymol inhibits the reaction [imidacloprid results in decreased expression of HSD17B3 mRNA]

NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2

decreases expression

imidacloprid results in decreased expression of HSD3B2 mRNA

NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852

G

heat shock protein 90 beta family member 1

decreases expression

imidacloprid results in decreased expression of HSP90B1 protein

NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788

G

heat shock protein family A (Hsp70) member 1B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPA1B mRNA

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

heat shock protein family A (Hsp70) member 5

decreases expression

imidacloprid results in decreased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family B (small) member 1

decreases expression

imidacloprid results in decreased expression of HSPB1 protein

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

heat shock protein family B (small) member 7

decreases expression

imidacloprid results in decreased expression of HSPB7 mRNA

NCBI chr 5:153,727,782...153,731,268
Ensembl chr 5:153,727,588...153,731,266

G

HSPA (Hsp70) binding protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPBP1 mRNA

NCBI chr 1:69,165,394...69,189,062
Ensembl chr 1:69,165,572...69,244,593

G

5-hydroxytryptamine receptor 2C

increases expression

imidacloprid results in increased expression of HTR2C mRNA

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

immediate early response 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

interferon alpha 12 like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of IFNA12L gene

NCBI chr 5:103,476,362...103,477,427
Ensembl chr 5:103,476,657...103,477,211
Ensembl chr 5:103,476,657...103,477,211
Ensembl chr 5:103,476,657...103,477,211

G

insulin-like growth factor binding protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

immunoglobulin kappa variable 2-112 like 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of IGKV2-112L2 gene

NCBI chr 4:102,208,069...102,208,647
Ensembl chr 4:102,208,044...102,208,785

G

interleukin 10

multiple interactions
decreases expression

Plant Extracts inhibits the reaction [imidacloprid results in decreased expression of IL10 mRNA]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

increases expression
multiple interactions

imidacloprid results in increased expression of IL1B mRNA
Plant Extracts inhibits the reaction [imidacloprid results in increased expression of IL1B mRNA]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
increases expression

Plant Extracts inhibits the reaction [imidacloprid results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inositol polyphosphate-5-phosphatase F

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of INPP5F mRNA

NCBI chr 1:183,190,480...183,270,276
Ensembl chr 1:183,190,480...183,270,276

G

insulin 1

decreases expression
increases secretion
multiple interactions

imidacloprid results in decreased expression of INS1 protein
imidacloprid results in increased secretion of INS1 protein
Dietary Fats promotes the reaction [imidacloprid results in increased secretion of INS1 protein]; imidacloprid promotes the reaction [Dietary Fats results in increased secretion of INS1 protein]

PMID:27960282 PMID:28850943

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

IQ motif containing B1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IQCB1 mRNA

NCBI chr11:63,905,595...63,960,141
Ensembl chr11:63,905,590...63,960,093

G

interferon regulatory factor 2 binding protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IRF2BP2 mRNA

NCBI chr19:54,559,417...54,565,096
Ensembl chr19:54,560,128...54,566,642

G

inositol 1,4,5-trisphosphate receptor interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ITPRIP mRNA

NCBI chr 1:246,762,804...246,786,379
Ensembl chr 1:246,762,472...246,786,408

G

ITPRIP like 1

decreases expression

imidacloprid results in decreased expression of ITPRIPL1 mRNA

NCBI chr 3:114,403,123...114,407,917
Ensembl chr 3:114,402,270...114,414,497

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of JUNB mRNA

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

katanin interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KATNIP gene

NCBI chr 1:180,270,194...180,436,766
Ensembl chr 1:180,269,929...180,436,766

G

Kelch-like ECH-associated protein 1

decreases expression

imidacloprid results in decreased expression of KEAP1 mRNA

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

KH domain containing 4, pre-mRNA splicing factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KHDC4 mRNA

NCBI chr 2:174,149,059...174,177,816
Ensembl chr 2:174,149,141...174,177,504

G

KLF transcription factor 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KLF10 mRNA

NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994

G

KLF transcription factor 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of KLF2 mRNA

NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944

G

kelch-like family member 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KLHL10 gene

NCBI chr10:85,376,442...85,392,720
Ensembl chr10:85,376,442...85,392,720

G

kallikrein 1

decreases expression

imidacloprid results in decreased expression of KLK1 mRNA

NCBI chr 1:94,642,644...94,646,760
Ensembl chr 1:94,642,687...94,646,754

G

keratin 5

decreases expression

imidacloprid results in decreased expression of KRT5 mRNA

NCBI chr 7:132,846,132...132,851,861
Ensembl chr 7:132,846,136...132,851,850

G

leptin

multiple interactions
increases secretion

Dietary Fats promotes the reaction [imidacloprid results in increased secretion of LEP protein]; imidacloprid promotes the reaction [Dietary Fats results in increased secretion of LEP protein]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

galectin-like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LGALSL mRNA

NCBI chr14:94,996,991...95,004,499
Ensembl chr14:94,996,990...95,004,980

G

luteinizing hormone subunit beta

multiple interactions
increases expression

Thymol inhibits the reaction [imidacloprid results in increased expression of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

LIM homeobox 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of LHX2 gene

NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908

G

LIF, interleukin 6 family cytokine

multiple interactions

LIF protein affects the reaction [imidacloprid affects the methylation of APC promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of CDH1 promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of CDKN2A promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of MLH1 promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of RARB promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of TIMP3 promoter]

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

lipopolysaccharide-induced TNF factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LITAF mRNA

NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763

G

ligand of numb-protein X 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LNX2 mRNA

NCBI chr12:8,005,202...8,070,494
Ensembl chr12:8,005,227...8,070,494

G

lysyl oxidase-like 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LOXL3 gene

NCBI chr 4:115,540,640...115,556,958
Ensembl chr 4:115,540,685...115,557,466

G

lysophosphatidylcholine acyltransferase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPCAT1 gene

NCBI chr 1:29,766,070...29,816,401
Ensembl chr 1:29,766,071...29,816,401

G

lysophosphatidylglycerol acyltransferase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPGAT1 gene

NCBI chr13:103,294,622...103,365,372
Ensembl chr13:103,294,528...103,362,333

G

lipin 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LPIN3 mRNA

NCBI chr 3:149,533,719...149,558,494
Ensembl chr 3:149,534,051...149,558,327

G

leukotriene A4 hydrolase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LTA4H mRNA

NCBI chr 7:27,969,796...28,001,600
Ensembl chr 7:27,969,789...28,001,600

G

leucine rich adaptor protein 1-like

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LURAP1L gene

NCBI chr 5:95,362,005...95,409,439
Ensembl chr 5:95,362,005...95,409,438

G

Ly6/neurotoxin 1

multiple interactions

LYNX1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]

NCBI chr 7:106,632,800...106,638,003
Ensembl chr 7:106,632,797...106,638,023

G

Ly6/Plaur domain containing 1

multiple interactions

LYPD1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]

NCBI chr13:37,326,459...37,368,515
Ensembl chr13:37,326,464...37,368,493

G

lysozyme 2

multiple interactions
decreases activity

Plant Extracts inhibits the reaction [imidacloprid results in decreased activity of LYZ protein]

NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106

G

MAGE family member L2

increases expression

imidacloprid results in increased expression of MAGEL2 mRNA

NCBI chr 1:115,880,142...115,884,684
Ensembl chr 1:115,880,474...115,884,250

G

mitogen activated protein kinase 1

increases phosphorylation

imidacloprid results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases phosphorylation

imidacloprid results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

increases expression

imidacloprid results in increased expression of MAPK8 mRNA

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

MAPK activated protein kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MAPKAPK2 mRNA

NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457

G

meiosis regulator and mRNA stability factor 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MARF1 mRNA

NCBI chr10:888,053...932,760
Ensembl chr10:888,076...932,753

G

myoglobin

decreases expression

imidacloprid results in decreased expression of MB mRNA

NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383

G

mediator complex subunit 12L

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MED12L mRNA

NCBI chr 2:143,253,048...143,576,507
Ensembl chr 2:143,252,139...143,573,741

G

methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of METTL14 mRNA

NCBI chr 2:211,530,598...211,546,845
Ensembl chr 2:211,530,602...211,546,821

G

microfibril associated protein 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of MFAP5 gene

NCBI chr 4:155,727,925...155,750,458
Ensembl chr 4:155,727,925...155,750,458

G

macrophage migration inhibitory factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIF mRNA

NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504

G

microRNA 122

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR122 mRNA

NCBI chr18:58,758,703...58,758,787

G

microRNA 130a

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR130A mRNA

NCBI chr 3:69,822,542...69,822,629
Ensembl chr 3:69,822,542...69,822,629

G

microRNA 146a

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR146A mRNA

NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610

G

microRNA 193

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR193 mRNA

NCBI chr10:64,672,354...64,672,439

G

microRNA 22

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR22 mRNA

NCBI chr10:60,307,039...60,307,133
Ensembl chr10:60,307,039...60,307,133

G

microRNA 32

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR32 mRNA

NCBI chr 5:71,596,083...71,596,152
Ensembl chr 5:71,596,083...71,596,152

G

microRNA 33

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR33 mRNA

NCBI chr 7:113,713,855...113,713,923
Ensembl chr 7:113,713,855...113,713,923

G

microRNA 486

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR486 mRNA

G

mutL homolog 1

multiple interactions
affects methylation

LIF protein affects the reaction [imidacloprid affects the methylation of MLH1 promoter]

NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617

G

malonyl-CoA decarboxylase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MLYCD mRNA

NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793

G

molybdenum cofactor synthesis 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MOCS2 mRNA

NCBI chr 2:46,504,588...46,516,327
Ensembl chr 2:46,504,588...46,516,324

G

MORC family CW-type zinc finger 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MORC3 mRNA

NCBI chr11:33,151,906...33,194,650
Ensembl chr11:33,152,025...33,194,646

G

myeloperoxidase

increases expression

imidacloprid results in increased expression of MPO protein

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

MRG domain binding protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRGBP mRNA

NCBI chr 3:167,697,129...167,700,592
Ensembl chr 3:167,697,185...167,700,592

G

MRN complex interacting protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRNIP mRNA

NCBI chr10:34,501,359...34,525,474
Ensembl chr10:34,501,384...34,525,469

G

mitochondrial ribosomal protein L44

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPL44 mRNA

NCBI chr 9:81,106,658...81,111,709
Ensembl chr 9:81,106,655...81,112,812

G

mitochondrial ribosomal protein S18B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPS18B mRNA

NCBI chr20:2,838,174...2,844,260
Ensembl chr20:2,838,030...2,844,260

G

mitochondrial amidoxime reducing component 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MTARC1 mRNA

NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796

G

myosin binding protein C2

increases expression

imidacloprid results in increased expression of MYBPC2 mRNA

NCBI chr 1:94,994,121...95,017,584
Ensembl chr 1:94,994,104...95,017,584

G

myosin X

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MYO10 mRNA

NCBI chr 2:76,100,989...76,305,619
Ensembl chr 2:76,100,987...76,303,030

G

myopalladin

decreases expression

imidacloprid results in decreased expression of MYPN mRNA

NCBI chr20:25,429,898...25,522,443
Ensembl chr20:25,436,843...25,522,443

G

NEDD4 binding protein 2-like 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of N4BP2L2 mRNA

NCBI chr12:137,342...200,292
Ensembl chr12:103,590...197,784

G

NEDD8 activating enzyme E1 subunit 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NAE1 mRNA

NCBI chr19:446,015...472,145
Ensembl chr19:446,000...472,371

G

NADH:ubiquinone oxidoreductase complex assembly factor 2

decreases expression

imidacloprid results in decreased expression of NDUFAF2 mRNA

NCBI chr 2:39,535,680...39,647,378
Ensembl chr 2:39,535,689...39,647,316

G

NADH:ubiquinone oxidoreductase subunit B11

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of NDUFB11 gene

NCBI chr X:1,572,805...1,575,063
Ensembl chr X:1,572,785...1,575,062

G

neurogenin 3

decreases expression

imidacloprid results in decreased expression of NEUROG3 mRNA

NCBI chr20:30,079,780...30,081,262
Ensembl chr20:30,079,780...30,081,262

G

nuclear factor, erythroid 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NFE2 mRNA

NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108

G

nuclear factor, interleukin 3 regulated

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NFIL3 mRNA

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D1 mRNA

NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705

G

nuclear receptor subfamily 1, group D, member 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D2 mRNA

NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553

G

nuclear receptor subfamily 1, group I, member 3

decreases abundance

NR1I3 results in decreased abundance of imidacloprid

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor subfamily 5, group A, member 1

decreases expression

imidacloprid results in decreased expression of NR5A1 mRNA

NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328

G

nuclear casein kinase and cyclin-dependent kinase substrate 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NUCKS1 mRNA

NCBI chr13:43,345,091...43,374,316
Ensembl chr13:43,345,115...43,370,229

G

2'-5'-oligoadenylate synthetase-like

increases expression

imidacloprid results in increased expression of OASL mRNA

NCBI chr12:41,682,900...41,695,641
Ensembl chr12:41,682,900...41,695,641

G

8-oxoguanine DNA glycosylase

increases expression

imidacloprid results in increased expression of OGG1 mRNA

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

olfactory receptor 943

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of OLR943 gene

NCBI chr 7:3,389,336...3,390,274
Ensembl chr 7:3,388,200...3,392,130

G

5-oxoprolinase (ATP-hydrolysing)

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of OPLAH mRNA

NCBI chr 7:108,011,472...108,051,751
Ensembl chr 7:108,011,475...108,035,297

G

ORAI calcium release-activated calcium modulator 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ORAI3 gene

NCBI chr 1:182,381,196...182,386,055
Ensembl chr 1:182,344,293...182,386,052

G

PP2A Aalpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PABIR1 gene

NCBI chr 1:222,114,988...222,116,294
Ensembl chr 1:222,112,591...222,116,396

G

PARP1 binding protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of PARPBP gene

NCBI chr 7:22,511,427...22,580,834
Ensembl chr 7:22,511,427...22,573,695

G

phosphoenolpyruvate carboxykinase 2 (mitochondrial)

increases expression
multiple interactions

imidacloprid results in increased expression of PCK2 mRNA
Dietary Fats promotes the reaction [imidacloprid results in increased expression of PCK2 mRNA]; imidacloprid promotes the reaction [Dietary Fats results in increased expression of PCK2 mRNA]

NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283

G

proliferating cell nuclear antigen

multiple interactions
decreases expression

Thymol inhibits the reaction [imidacloprid results in decreased expression of PCNA protein]

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

pyruvate dehydrogenase kinase 4

increases expression

imidacloprid results in increased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

PDZ and LIM domain 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PDLIM1 mRNA

NCBI chr 1:239,042,372...239,091,074
Ensembl chr 1:239,042,385...239,091,076

G

pyruvate dehydrogenase phosphatase catalytic subunit 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PDP1 mRNA

NCBI chr 5:25,446,843...25,455,107
Ensembl chr 5:25,446,272...25,455,217

G

PDZ domain containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PDZD2 gene

NCBI chr 2:61,384,614...61,770,516
Ensembl chr 2:61,386,381...61,770,524

G

period circadian regulator 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PER1 mRNA

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PER3 mRNA

NCBI chr 5:161,460,228...161,495,404
Ensembl chr 5:161,459,533...161,495,607

G

phosphoglycerate kinase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PGK1 mRNA

NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418

G

progesterone receptor

affects expression

imidacloprid affects the expression of PGR mRNA

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

protein inhibitor of activated STAT, 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIAS3 mRNA

NCBI chr 2:184,232,546...184,241,455
Ensembl chr 2:184,232,571...184,241,480

G

phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIP4P1 mRNA

NCBI chr15:24,146,854...24,150,739
Ensembl chr15:24,146,856...24,150,702

G

paired Ig-like receptor B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LILRB3 mRNA

NCBI chr 1:65,499,195...65,506,666
Ensembl chr 1:65,499,195...65,506,666

G

pleckstrin homology and RhoGEF domain containing G5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLEKHG5 mRNA

NCBI chr 5:162,577,999...162,621,518
Ensembl chr 5:162,578,071...162,621,513

G

polo-like kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLK2 mRNA

NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947

G

phospholipid phosphatase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PLPP4 gene

NCBI chr 1:183,829,794...183,959,319
Ensembl chr 1:183,830,409...183,959,319

G

phosphomevalonate kinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PMVK mRNA

NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364

G

PNKD metallo-beta-lactamase domain containing

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNKD mRNA

NCBI chr 9:75,868,620...75,937,126
Ensembl chr 9:75,867,468...75,937,124

G

phenylethanolamine-N-methyltransferase

multiple interactions
increases expression

imidacloprid promotes the reaction [Nicotine results in increased expression of PNMT protein]
imidacloprid results in increased expression of PNMT protein

NCBI chr10:83,383,019...83,386,557
Ensembl chr10:83,384,923...83,386,556

G

proline-rich nuclear receptor coactivator 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNRC1 mRNA

NCBI chr 5:47,647,070...47,657,832
Ensembl chr 5:47,647,071...47,650,161

G

cytochrome p450 oxidoreductase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of POR gene

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

peroxisome proliferator activated receptor alpha

decreases expression

imidacloprid results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor delta

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PPARD mRNA

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

PPARG coactivator 1 alpha

decreases expression

imidacloprid results in decreased expression of PPARGC1A protein

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

PR/SET domain 15

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRDM15 mRNA

NCBI chr11:37,164,608...37,225,172
Ensembl chr11:37,165,575...37,222,207

G

PRELI domain containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELID2 mRNA

NCBI chr18:33,869,934...33,961,320
Ensembl chr18:33,873,599...33,961,225

G

proline and arginine rich end leucine rich repeat protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELP mRNA

NCBI chr13:45,368,407...45,391,480
Ensembl chr13:45,370,533...45,380,270

G

prolactin

multiple interactions

[mancozeb co-treated with imidacloprid] results in increased expression of PRL protein

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

proline and serine rich 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PROSER2 mRNA

NCBI chr17:72,151,961...72,187,524
Ensembl chr17:72,151,872...72,185,825

G

pre-mRNA processing factor 39

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRPF39 mRNA

NCBI chr 6:83,088,981...83,113,826
Ensembl chr 6:83,088,986...83,113,825

G

proteasome 26S subunit, ATPase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC2 mRNA

NCBI chr 4:13,255,850...13,270,160
Ensembl chr 4:13,255,856...13,270,185

G

proteasome 26S subunit, ATPase 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC4 mRNA

NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494

G

proteasome 26S subunit, ATPase 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC5 mRNA

NCBI chr10:91,187,763...91,193,697
Ensembl chr10:91,187,743...91,213,135

G

protein phosphatase 2 phosphatase activator

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PTPA mRNA

NCBI chr 3:13,689,742...13,720,287
Ensembl chr 3:13,689,741...13,722,549

G

pseudouridine synthase 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PUS10 mRNA

NCBI chr14:97,621,228...97,684,059
Ensembl chr14:97,621,391...97,684,046

G

rabaptin, RAB GTPase binding effector protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABEP1 mRNA

NCBI chr10:55,566,156...55,667,595
Ensembl chr10:55,566,185...55,665,973

G

RAB, member of RAS oncogene family like 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABL2 mRNA

NCBI chr 7:120,652,175...120,660,906
Ensembl chr 7:120,652,175...120,660,783

G

RNA guanine-7 methyltransferase activating subunit

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RAMAC gene

NCBI chr 1:135,708,529...135,714,417
Ensembl chr 1:135,708,535...135,722,151

G

RAN GTPase activating protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RANGAP1 mRNA

NCBI chr 7:113,224,695...113,250,441
Ensembl chr 7:113,224,703...113,250,438

G

retinoic acid receptor, beta

multiple interactions
affects methylation

LIF protein affects the reaction [imidacloprid affects the methylation of RARB promoter]

NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288

G

arginyl-tRNA synthetase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RARS1 mRNA

NCBI chr10:20,270,744...20,295,192
Ensembl chr10:20,270,483...20,295,196

G

RNA binding fox-1 homolog 2

increases expression

imidacloprid results in increased expression of RBFOX2 mRNA

NCBI chr 7:108,810,627...109,054,420
Ensembl chr 7:108,810,628...109,054,691

G

RNA binding motif protein 14

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RBM14 mRNA

NCBI chr 1:202,076,940...202,105,688
Ensembl chr 1:202,078,287...202,105,665

G

RNA binding motif protein 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RBM3 mRNA

NCBI chr X:14,348,909...14,352,387
Ensembl chr X:14,348,910...14,353,580

G

RNA binding protein, mRNA processing factor

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RBPMS gene

NCBI chr16:58,239,370...58,395,424
Ensembl chr16:58,239,474...58,395,426

G

RELA proto-oncogene, NF-kB subunit

increases expression

imidacloprid results in increased expression of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

retroelement silencing factor 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RESF1 mRNA

NCBI chr 4:182,325,913...182,362,054
Ensembl chr 4:182,335,454...182,362,054

G

REV1, DNA directed polymerase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of REV1 mRNA

NCBI chr 9:40,278,100...40,351,764
Ensembl chr 9:40,278,101...40,351,576

G

regulatory factor X, 7

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RFX7 mRNA

NCBI chr 8:73,254,051...73,339,209
Ensembl chr 8:73,254,051...73,339,209

G

regulator of cell cycle

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RGCC gene

NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141

G

regulator of G-protein signaling 16

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RGS16 mRNA

NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857

G

Rho-related BTB domain containing 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RHOBTB3 mRNA

NCBI chr 2:5,363,388...5,419,164
Ensembl chr 2:5,363,388...5,419,041

G

ribonuclease A family member 10

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RNASE10 gene

NCBI chr15:24,226,687...24,229,149
Ensembl chr15:24,226,691...24,228,561

G

Rho family GTPase 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RND3 gene; [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RND3 mRNA

NCBI chr 3:35,571,929...35,589,283
Ensembl chr 3:35,571,143...35,589,327

G

RAR-related orphan receptor C

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RORC mRNA

NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907

G

ribitol xylosyltransferase 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RXYLT1 gene

NCBI chr 7:57,770,841...57,782,695
Ensembl chr 7:57,770,842...57,782,657

G

spalt-like transcription factor 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SALL4 gene

NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822

G

sarcosine dehydrogenase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SARDH mRNA

NCBI chr 3:10,510,553...10,575,342
Ensembl chr 3:10,510,553...10,573,874

G

sodium channel epithelial 1 subunit alpha

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SCNN1A mRNA

NCBI chr 4:158,122,962...158,146,184
Ensembl chr 4:158,122,962...158,146,181

G

short chain dehydrogenase/reductase family 42E, member 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SDR42E1 mRNA

NCBI chr19:45,715,366...45,727,901
Ensembl chr19:45,715,399...45,727,901

G

serpin family A member 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SERPINA1 mRNA

NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339

G

sestrin 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SESN2 mRNA

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

SET domain containing 6, protein lysine methyltransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SETD6 mRNA

NCBI chr19:9,343,309...9,350,477
Ensembl chr19:9,347,458...9,350,453

G

secreted frizzled-related protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SFRP2 gene

NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063

G

SH3-domain binding protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SH3BP2 mRNA

NCBI chr14:76,176,097...76,213,300
Ensembl chr14:76,176,101...76,213,251

G

single Ig and TIR domain containing

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SIGIRR mRNA

NCBI chr 1:196,195,363...196,208,692
Ensembl chr 1:196,199,462...196,202,269

G

salt-inducible kinase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SIK2 mRNA

NCBI chr 8:51,225,543...51,325,343
Ensembl chr 8:51,225,543...51,325,415

G

sirtuin 1

decreases expression

imidacloprid results in decreased expression of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 12, member 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC12A6 mRNA

NCBI chr 3:99,071,577...99,170,266
Ensembl chr 3:99,071,391...99,170,258

G

solute carrier family 20 member 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC20A1 mRNA

NCBI chr 3:116,427,095...116,441,049
Ensembl chr 3:116,427,098...116,441,051

G

solute carrier family 22 member 1

increases activity

imidacloprid results in increased activity of SLC22A1 protein

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22 member 2

decreases activity

imidacloprid results in decreased activity of SLC22A2 protein

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 22 member 8

decreases activity

imidacloprid results in decreased activity of SLC22A8 protein

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

solute carrier family 25, member 39

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC25A39 mRNA

NCBI chr10:87,362,494...87,367,358
Ensembl chr10:87,362,490...87,367,260

G

solute carrier family 26 member 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC26A6 mRNA

NCBI chr 8:109,558,968...109,569,778
Ensembl chr 8:109,559,642...109,569,778

G

solute carrier family 2 member 2

increases expression

imidacloprid results in increased expression of SLC2A2 mRNA

NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933

G

solute carrier family 2 member 3

increases expression

imidacloprid results in increased expression of SLC2A3 mRNA

NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472

G

solute carrier family 2 member 4

decreases expression

imidacloprid results in decreased expression of SLC2A4 mRNA
imidacloprid results in decreased expression of SLC2A4 mRNA; imidacloprid results in decreased expression of SLC2A4 protein

PMID:27960282 PMID:28850943 PMID:32685429

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 37 member 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC37A2 mRNA

NCBI chr 8:36,945,787...36,971,748
Ensembl chr 8:36,946,930...36,971,482

G

STE20-like kinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SLK gene

NCBI chr 1:246,473,712...246,529,643
Ensembl chr 1:246,473,712...246,526,530

G

SMAD family member 7

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SMAD7 mRNA

NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765

G

small muscle protein, X-linked

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SMPX gene

NCBI chr X:37,233,209...37,292,266
Ensembl chr X:37,234,294...37,276,708

G

small nuclear ribonucleoprotein U5 subunit 200

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SNRNP200 mRNA

NCBI chr 3:114,428,854...114,458,194
Ensembl chr 3:114,428,854...114,458,182

G

sorting nexin 4

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SNX4 mRNA

NCBI chr11:67,460,872...67,518,143
Ensembl chr11:67,460,870...67,518,174

G

suppressor of cytokine signaling 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SOCS3 mRNA

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

superoxide dismutase 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SOD3 mRNA

NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990

G

spermatogenesis and oogenesis specific basic helix-loop-helix 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SOHLH1 gene

NCBI chr 3:8,662,995...8,667,521
Ensembl chr 3:8,663,318...8,667,388

G

sperm associated antigen 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SPAG1 mRNA

NCBI chr 7:67,361,474...67,421,369
Ensembl chr 7:67,361,477...67,421,368

G

steroid 5 alpha-reductase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SRD5A2 gene

NCBI chr 6:21,426,225...21,465,727
Ensembl chr 6:21,426,215...21,462,112

G

sterol regulatory element binding transcription factor 1

increases expression

imidacloprid results in increased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

serine/arginine repetitive matrix 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRRM2 mRNA

NCBI chr10:12,815,471...12,848,750
Ensembl chr10:12,815,471...12,848,751

G

serine and arginine rich splicing factor 5

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRSF5 mRNA

NCBI chr 6:100,605,165...100,610,192
Ensembl chr 6:100,605,456...100,610,177

G

steroidogenic acute regulatory protein

decreases expression
multiple interactions

imidacloprid results in decreased expression of STAR mRNA
Thymol inhibits the reaction [imidacloprid results in decreased expression of STAR mRNA]

PMID:31780179 PMID:34171690

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

StAR-related lipid transfer domain containing 9

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of STARD9 mRNA

NCBI chr 3:107,581,097...107,672,746
Ensembl chr 3:107,581,164...107,673,898

G

sushi domain containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SUSD2 mRNA

NCBI chr20:13,017,516...13,024,820
Ensembl chr20:13,017,477...13,024,903

G

symplekin scaffold protein

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SYMPK mRNA

NCBI chr 1:78,672,372...78,700,684
Ensembl chr 1:78,672,378...78,700,684

G

tachykinin receptor 3

increases expression

imidacloprid results in increased expression of TACR3 mRNA

NCBI chr 2:223,266,536...223,363,791
Ensembl chr 2:223,266,536...223,363,791

G

transcriptional adaptor 2B

increases expression

imidacloprid results in increased expression of TADA2B mRNA

NCBI chr14:74,279,286...74,290,758
Ensembl chr14:74,279,217...74,290,755

G

tyrosine aminotransferase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TAT mRNA

NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031

G

tyrosyl-DNA phosphodiesterase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TDP2 mRNA

NCBI chr17:40,228,943...40,240,337
Ensembl chr17:40,228,947...40,240,313

G

TEA domain transcription factor 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TEAD2 mRNA

NCBI chr 1:95,702,366...95,719,186
Ensembl chr 1:95,703,005...95,719,186

G

trans-2,3-enoyl-CoA reductase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TECR mRNA

NCBI chr19:24,526,700...24,568,168
Ensembl chr19:24,541,615...24,568,168

G

TDP-glucose 4,6-dehydratase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TGDS mRNA

NCBI chr15:95,175,064...95,195,555
Ensembl chr15:95,174,608...95,195,554

G

transforming growth factor, beta induced

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TGFBI mRNA

NCBI chr17:7,955,603...7,984,903
Ensembl chr17:7,955,603...7,985,240

G

tyrosine hydroxylase

multiple interactions
increases expression

[conotoxin AuIB co-treated with triethyl-(beta-4-stilbenoxyethyl)ammonium co-treated with ZM 241385] inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; [conotoxin AuIB co-treated with triethyl-(beta-4-stilbenoxyethyl)ammonium co-treated with ZM 241385] inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with exoenzyme C3, Clostridium botulinum] inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; conotoxin AuIB inhibits the reaction [imidacloprid promotes the reaction [Acetylcholine results in increased expression of TH mRNA]]; conotoxin AuIB inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; conotoxin AuIB inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; exoenzyme C3, Clostridium botulinum inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Acetylcholine results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Nicotine results in increased expression of TH protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [imidacloprid promotes the reaction [Acetylcholine results in increased expression of TH mRNA]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; ZM 241385 inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; ZM 241385 inhibits the reaction [imidacloprid results in increased expression of TH mRNA]
imidacloprid results in increased expression of TH mRNA; imidacloprid results in increased expression of TH protein

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

thyroid hormone receptor beta

affects binding

imidacloprid binds to THRB protein

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

TIMP metallopeptidase inhibitor 3

affects methylation
multiple interactions

imidacloprid affects the methylation of TIMP3 promoter
LIF protein affects the reaction [imidacloprid affects the methylation of TIMP3 promoter]

NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839

G

tight junction associated protein 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TJAP1 mRNA

NCBI chr 9:14,701,418...14,725,623
Ensembl chr 9:14,701,468...14,725,751

G

tight junction protein 1

decreases expression

imidacloprid results in decreased expression of TJP1 mRNA

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

thymidine kinase 1

increases mutagenesis

imidacloprid results in increased mutagenesis of TK1 gene

NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920

G

transketolase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TKT mRNA

NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698

G

transmembrane BAX inhibitor motif containing 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TMBIM6 mRNA

NCBI chr 7:130,527,313...130,542,567
Ensembl chr 7:130,527,316...130,543,633

G

transmembrane protein 268

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TMEM268 mRNA

NCBI chr 5:76,974,827...77,001,457
Ensembl chr 5:76,977,310...77,001,452

G

thiol methyltransferase 1B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of METTL7B mRNA

NCBI chr 7:1,388,876...1,391,526
Ensembl chr 7:1,388,879...1,391,526

G

tumor necrosis factor

multiple interactions
increases expression

Dietary Fats promotes the reaction [imidacloprid results in increased expression of TNF mRNA]; imidacloprid promotes the reaction [Dietary Fats results in increased expression of TNF mRNA]
imidacloprid results in increased expression of TNF mRNA; imidacloprid results in increased expression of TNF protein
Plant Extracts inhibits the reaction [imidacloprid results in increased expression of TNF mRNA]

PMID:27960282 PMID:34993831 PMID:35398170

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TNFAIP2 mRNA

NCBI chr 6:130,476,832...130,489,914
Ensembl chr 6:130,476,889...130,489,914

G

troponin I2, fast skeletal type

decreases expression

imidacloprid results in decreased expression of TNNI2 mRNA

NCBI chr 1:197,595,012...197,597,554
Ensembl chr 1:197,594,813...197,597,560

G

torsin family 3, member A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TOR3A mRNA

NCBI chr13:68,769,893...68,798,738
Ensembl chr13:68,769,605...68,798,475

G

Traf3 interacting protein 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAF3IP2 mRNA

NCBI chr20:43,011,405...43,054,654
Ensembl chr20:43,011,450...43,054,667

G

TRAF type zinc finger domain containing 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAFD1 mRNA

NCBI chr12:35,165,606...35,179,525
Ensembl chr12:35,165,606...35,179,525

G

tripartite motif-containing 34

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRIM34 mRNA

NCBI chr 1:158,707,172...158,720,214
Ensembl chr 1:158,707,172...158,718,674

G

TSC22 domain family, member 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TSC22D3 mRNA

NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861

G

thyroid stimulating hormone subunit beta

multiple interactions

[mancozeb co-treated with imidacloprid] results in increased expression of TSHB protein

NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559

G

translocator protein

decreases expression

imidacloprid results in decreased expression of TSPO mRNA

NCBI chr 7:114,720,188...114,730,450
Ensembl chr 7:114,720,188...114,730,450

G

TXK tyrosine kinase

increases expression

imidacloprid results in increased expression of TXK mRNA

NCBI chr14:35,463,369...35,519,448
Ensembl chr14:35,463,944...35,519,448

G

ubiquitin-like modifier activating enzyme 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UBA3 mRNA

NCBI chr 4:129,789,526...129,810,707
Ensembl chr 4:129,789,204...129,810,606

G

ubiquitin B

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBB mRNA

NCBI chr10:47,247,630...47,249,335
Ensembl chr10:47,245,637...47,249,333

G

ubiquitin C

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBC mRNA

NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925

G

uridine-cytidine kinase 1-like 1

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UCKL1 mRNA

NCBI chr 3:168,674,849...168,687,513
Ensembl chr 3:168,674,849...168,698,091

G

unc-45 myosin chaperone A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UNC45A mRNA

NCBI chr 1:134,281,930...134,296,661
Ensembl chr 1:134,281,933...134,301,586

G

unc-45 myosin chaperone B

decreases expression

imidacloprid results in decreased expression of UNC45B mRNA

NCBI chr10:67,845,464...67,873,143
Ensembl chr10:67,845,462...67,873,389

G

ubiquitin specific peptidase 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of USP2 mRNA

NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331

G

ubiquitin specific peptidase 40

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of USP40 mRNA

NCBI chr 9:88,607,920...88,678,940
Ensembl chr 9:88,607,930...88,678,914

G

vinculin

decreases expression

imidacloprid results in decreased expression of VCL mRNA

NCBI chr15:3,265,776...3,355,586
Ensembl chr15:3,265,815...3,355,606

G

vascular endothelial growth factor A

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vanin 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VNN3 mRNA

NCBI chr 1:21,571,364...21,583,626
Ensembl chr 1:21,571,364...21,583,626

G

vitronectin

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VTN mRNA

NCBI chr10:63,394,732...63,397,812
Ensembl chr10:63,394,719...63,397,810

G

WD repeat domain 11

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of WDR11 gene

NCBI chr 1:184,165,260...184,210,834
Ensembl chr 1:184,165,571...184,210,846

G

WEE1 G2 checkpoint kinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of WEE1 mRNA

NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688

G

WAP four-disulfide core domain 9

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of WFDC9 gene

NCBI chr 3:153,380,554...153,389,055
Ensembl chr 3:153,380,649...153,391,261

G

YOD1 deubiquitinase

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of YOD1 gene

NCBI chr13:42,175,047...42,181,661
Ensembl chr13:42,174,820...42,177,205

G

zinc finger, C3H1-type containing

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFC3H1 mRNA

NCBI chr 7:51,008,251...51,064,666
Ensembl chr 7:51,007,984...51,064,661

G

zinc finger protein 280D

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP280D mRNA

NCBI chr 8:72,992,655...73,080,482
Ensembl chr 8:72,992,650...73,080,480

G

zinc finger protein 36, C3H type-like 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP36L2 mRNA

NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064

G

zinc finger protein 422

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP422 mRNA

NCBI chr 4:149,885,805...149,893,287
Ensembl chr 4:149,885,600...149,893,257

G

zinc finger protein 598

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP598 mRNA

NCBI chr10:13,694,224...13,706,235
Ensembl chr10:13,694,286...13,706,233

G

zinc finger MYM-type containing 3

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM3 mRNA

NCBI chr X:66,528,585...66,544,234
Ensembl chr X:66,528,585...66,544,782

G

zinc finger MYM-type containing 6

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM6 mRNA

NCBI chr 5:139,396,374...139,444,357
Ensembl chr 5:139,396,727...139,444,279

G

zinc finger RANBP2-type containing 2

multiple interactions

[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZRANB2 mRNA

NCBI chr 2:246,573,110...246,586,942
Ensembl chr 2:246,573,166...246,586,942

imidapril

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin converting enzyme 2

increases response to substance

ACE2 gene SNP results in increased susceptibility to imidapril

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

carboxylesterase 1D

multiple interactions

CES1 protein results in increased hydrolysis of and results in increased activity of imidapril; CES1 protein results in increased metabolism of and results in increased activity of imidapril; Dust inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril]; tert-butylphenyl diphenyl phosphate inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril]; triphenyl phosphate inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril]

PMID:9300133 PMID:31268531

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

cytochrome P450, family 11, subfamily b, polypeptide 3

affects response to substance

CYP11B2 gene polymorphism affects the susceptibility to imidapril

NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048

imidaprilat

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensinogen

multiple interactions

imidaprilat inhibits the reaction [AGT protein results in increased activity of and results in increased localization of PRKCA protein]

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

protein kinase C, alpha

multiple interactions

imidaprilat inhibits the reaction [AGT protein results in increased activity of and results in increased localization of PRKCA protein]

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

imiprothrin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

decreases expression

imiprothrin results in decreased expression of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

imiprothrin results in increased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

glutamic--pyruvic transaminase

increases expression

imiprothrin results in increased expression of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

iprodione

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

iprodione binds to and results in increased activity of AHR protein

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aldehyde dehydrogenase 2 family member

multiple interactions

[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

annexin A10

increases expression

iprodione results in increased expression of ANXA10 mRNA

NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648

G

androgen receptor

multiple interactions
affects binding

[iprodione binds to and results in decreased activity of AR protein] inhibits the reaction [Metribolone binds to AR protein]; iprodione inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; iprodione inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]
iprodione binds to AR protein

PMID:19564212 PMID:33049310

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

iprodione results in decreased expression of BCL2 protein
Chlorpyrifos promotes the reaction [iprodione results in decreased expression of BCL2 protein]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of BCL2 protein]

PMID:33586219 PMID:34060014

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

increases expression
multiple interactions

iprodione results in increased expression of CASP3 protein
Chlorpyrifos promotes the reaction [iprodione results in increased expression of CASP3 protein]; iprodione promotes the reaction [Chlorpyrifos results in increased expression of CASP3 protein]

PMID:33586219 PMID:34060014

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cadherin 1

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in decreased expression of CDH1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in decreased expression of CDH1 protein

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

claudin 11

increases expression
multiple interactions

iprodione results in increased expression of CLDN11 protein
[carbendazim co-treated with iprodione] results in decreased expression of CLDN11 protein

NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050

G

cytochrome P450, family 19, subfamily a, polypeptide 1

increases activity

iprodione results in increased activity of CYP19A1 protein

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

iprodione results in increased expression of CYP1A1 mRNA; iprodione results in increased expression of CYP1A1 protein

PMID:16696176 PMID:32194361

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases expression

iprodione results in decreased expression of CYP2C19 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

iprodione results in decreased expression of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

DNA-damage inducible transcript 3

increases expression

iprodione results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

estrogen receptor 1

multiple interactions

iprodione binds to and results in increased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

iprodione binds to and results in increased activity of ESR2 protein

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

iprodione results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

follicle stimulating hormone subunit beta

multiple interactions
decreases expression

Chlorpyrifos inhibits the reaction [iprodione results in decreased expression of FSHB protein]; iprodione inhibits the reaction [Chlorpyrifos results in decreased expression of FSHB protein]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of FSHB protein]

PMID:33586219 PMID:34060014

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

growth arrest and DNA-damage-inducible, alpha

increases expression

iprodione results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

gap junction protein, alpha 1

multiple interactions

[carbendazim co-treated with iprodione] results in decreased expression of GJA1 protein

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

glutathione S-transferase alpha 2

increases expression

iprodione results in increased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

H2A.X variant histone

multiple interactions

[fludioxonil co-treated with cyprodinil co-treated with procymidone co-treated with iprodione co-treated with cyhalothrin] results in increased phosphorylation of H2AX protein; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in increased expression of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of H2AX protein

PMID:22389207 PMID:34503147 PMID:34830855

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

hydroxysteroid (17-beta) dehydrogenase 3

multiple interactions
decreases expression

[Chlorpyrifos co-treated with iprodione] results in decreased expression of HSD17B3 mRNA; [iprodione co-treated with Chlorpyrifos] results in decreased expression of HSD17B3 mRNA
iprodione results in decreased expression of HSD17B3 mRNA

PMID:33586219 PMID:34060014

NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554

G

heat shock protein family A (Hsp70) member 5

increases expression

iprodione results in increased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

luteinizing hormone subunit beta

multiple interactions
decreases expression

Chlorpyrifos inhibits the reaction [iprodione results in decreased expression of LHB protein]; iprodione inhibits the reaction [Chlorpyrifos results in decreased expression of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased activity of NR1I2 protein; iprodione binds to and results in increased activity of NR1I2 protein

PMID:25028461 PMID:33049310

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 5, group A, member 1

decreases expression
multiple interactions

iprodione results in decreased expression of NR5A1 mRNA
[iprodione co-treated with Chlorpyrifos] results in decreased expression of NR5A1 mRNA; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of NR5A1 mRNA]

PMID:33586219 PMID:34060014

NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328

G

peroxisome proliferator-activated receptor gamma

increases activity
multiple interactions

iprodione results in increased activity of PPARG protein
iprodione binds to and results in increased activity of PPARG protein

PMID:20143881 PMID:33049310

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

decreases expression
multiple interactions

iprodione results in decreased expression of PPARGC1A mRNA
Chlorpyrifos promotes the reaction [iprodione results in decreased expression of PPARGC1A mRNA]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of PPARGC1A mRNA]

PMID:33586219 PMID:34060014

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

sirtuin 1

multiple interactions
decreases expression

[iprodione co-treated with Chlorpyrifos] results in decreased expression of SIRT1 mRNA; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of SIRT1 mRNA]
iprodione results in decreased expression of SIRT1 mRNA

PMID:33586219 PMID:34060014

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

stathmin 1

increases expression

iprodione results in increased expression of STMN1 mRNA

NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154

G

telomerase reverse transcriptase

multiple interactions
decreases expression

[Chlorpyrifos co-treated with iprodione] results in decreased expression of TERT mRNA; [iprodione co-treated with Chlorpyrifos] results in decreased expression of TERT mRNA
iprodione results in decreased expression of TERT mRNA

PMID:33586219 PMID:34060014

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

thyroid hormone receptor alpha

multiple interactions

iprodione binds to and results in increased activity of THRA protein

NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936

G

thyroid hormone receptor beta

multiple interactions

iprodione binds to and results in increased activity of THRB protein

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

G

tumor necrosis factor

multiple interactions

Acetylcysteine inhibits the reaction [iprodione inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; iprodione inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53 binding protein 1

multiple interactions

[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] affects the expression of TP53BP1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] affects the expression of TP53BP1 protein

NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822

mephenytoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Mephenytoin results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily a, polypeptide 3

decreases activity

Mephenytoin results in decreased activity of CYP2A4 protein

NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases methylation
decreases activity
multiple interactions
increases metabolic processing

CYP2B6 protein results in decreased methylation of Mephenytoin
Mephenytoin results in decreased activity of CYP2B10 protein
Mephenytoin results in decreased activity of CYP2B6 protein
Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein]; Mephenytoin inhibits the reaction [CYP2B6 protein results in decreased ethylation of 7-ethoxy-4-trifluoromethylcoumarin]; Mephenytoin inhibits the reaction [CYP2B6 protein results in increased chemical synthesis of 7-hydroxy-4-trifluoromethylcoumarin]
CYP2B6 protein results in increased metabolism of Mephenytoin

PMID:9241656 PMID:12433797 PMID:12464242 PMID:18420780 PMID:25500267

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions
decreases activity
increases metabolic processing
increases oxidation
affects hydroxylation
affects metabolic processing
increases hydroxylation

4-amino-2-phenoxymethanesulfonanilide inhibits the reaction [CYP2C19 protein results in increased oxidation of Mephenytoin]; [CYP2C19 protein results in increased hydroxylation of Mephenytoin] which results in increased chemical synthesis of 4-hydroxymephenytoin; [CYP2C19 protein results in increased metabolism of Mephenytoin] which results in increased chemical synthesis of 4-hydroxymephenytoin; [Mephenytoin results in decreased activity of CYP2C19 protein] which results in decreased degradation of vanoxerine; Fluoxetine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Fluoxetine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; GH1 protein inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Lansoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Mephenytoin inhibits the reaction [CYP2C19 protein results in increased metabolism of 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide]; methyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin analog]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Pantoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; perfluorooctane sulfonic acid inhibits the reaction [CYP2C19 protein results in increased oxidation of Mephenytoin]; rabeprazole-thioether inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Resveratrol inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; sitaxsentan inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Tranylcypromine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Ursolic Acid inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; zafirlukast inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]
Mephenytoin results in decreased activity of CYP2C29 protein
CYP2C19 gene SNP affects the hydroxylation of Mephenytoin; CYP2C19 protein affects the hydroxylation of Mephenytoin
CYP2C19 protein affects the metabolism of Mephenytoin
CYP2C19 protein results in increased hydroxylation of Mephenytoin; CYP2C19 protein results in increased hydroxylation of Mephenytoin analog

PMID:3577206 PMID:9170147 PMID:11502731 PMID:11907490 PMID:12401345 More...

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity

Mephenytoin results in decreased activity of CYP2E1 protein

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

growth hormone 1

multiple interactions

GH1 protein inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

Mephenytoin binds to and results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

nilutamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases expression

nilutamide results in increased expression of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

androgen receptor

affects binding
increases response to substance
decreases activity
multiple interactions

nilutamide binds to AR protein
AR protein mutant form results in increased susceptibility to nilutamide
nilutamide results in decreased activity of AR protein
[AR protein mutant form results in increased susceptibility to nilutamide] which results in increased activity of AR protein mutant form; nilutamide analog binds to and affects the localization of AR protein; nilutamide binds to and results in decreased activity of AR protein; nilutamide inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; nilutamide inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; nilutamide inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; nilutamide inhibits the reaction [Metribolone results in increased activity of AR protein]; nilutamide inhibits the reaction [mibolerone affects the localization of AR protein]

PMID:15509168 PMID:16125883 PMID:16857237 PMID:18324785 PMID:18973785 More...

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

cyclin-dependent kinase inhibitor 1B

decreases expression

nilutamide results in decreased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

nilutamide results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

estrogen receptor 1

multiple interactions

nilutamide binds to and results in increased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

glyceraldehyde-3-phosphate dehydrogenase

multiple interactions

nilutamide inhibits the reaction [Dihydrotestosterone results in decreased activity of GAPDH protein]

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

growth regulating estrogen receptor binding 1

multiple interactions

nilutamide inhibits the reaction [Testosterone results in increased expression of GREB1 mRNA]

NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633

G

insulin-like growth factor 1 receptor

multiple interactions

nilutamide inhibits the reaction [Dihydrotestosterone results in decreased expression of IGF1R protein]

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

nilutamide binds to and results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

peroxisome proliferator-activated receptor gamma

multiple interactions

nilutamide binds to and results in increased activity of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

thyroid hormone receptor beta

multiple interactions

nilutamide binds to and results in increased activity of THRB protein

NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916

nitrofurantoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

Nitrofurantoin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Nitrofurantoin results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 4

decreases activity

Nitrofurantoin results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily G member 2

affects transport
affects abundance
multiple interactions
increases secretion
increases transport
affects response to substance
increases export

ABCG2 protein affects the transport of Nitrofurantoin
ABCG2 protein affects the abundance of Nitrofurantoin
chrysin inhibits the reaction [ABCG2 protein affects the transport of Nitrofurantoin]; Elacridar inhibits the reaction [ABCG2 protein affects the transport of Nitrofurantoin]
ABCG2 protein results in increased secretion of Nitrofurantoin
ABCG2 protein results in increased transport of Nitrofurantoin
ABCG2 results in increased secretion of Nitrofurantoin
chrysin inhibits the reaction [ABCG2 protein results in increased transport of Nitrofurantoin]
ABCG2 affects the susceptibility to Nitrofurantoin
chrysin inhibits the reaction [ABCG2 protein results in increased transport of Nitrofurantoin]; Nitrofurantoin inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]
ABCG2 protein results in increased export of Nitrofurantoin

PMID:15709111 PMID:15722455 PMID:17093006 PMID:17785426 PMID:18799806 More...

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

angiotensinogen

decreases activity

Nitrofurantoin results in decreased activity of AGT protein

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aldolase, fructose-bisphosphate A

increases expression

Nitrofurantoin results in increased expression of ALDOA mRNA; Nitrofurantoin results in increased expression of ALDOA protein

NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182

G

catalase

decreases activity

Nitrofurantoin results in decreased activity of CAT protein

PMID:1313237 PMID:9000262

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

ciliary neurotrophic factor

multiple interactions

Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]]

NCBI chr 1:209,887,854...209,889,877
Ensembl chr 1:209,887,854...209,889,877

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Nitrofurantoin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

Nitrofurantoin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
increases expression

NFE2L2 protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]; POR protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutathione-disulfide reductase

decreases activity
multiple interactions

Nitrofurantoin results in decreased activity of GSR protein
[Nitrofurantoin co-treated with GSR protein] affects the metabolism of Glucose

PMID:1313237 PMID:1901343 PMID:9000262

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

hypoxia inducible factor 1 subunit alpha

increases activity

Nitrofurantoin results in increased activity of HIF1A protein

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

heme oxygenase 1

increases expression

Nitrofurantoin results in increased expression of HMOX1 mRNA

PMID:7626009 PMID:11841787

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock transcription factor 1

increases activity

Nitrofurantoin results in increased activity of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

heat shock protein family A (Hsp70) member 8

increases expression

Nitrofurantoin results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

Nitrofurantoin results in increased expression of JUN mRNA

PMID:7626009 PMID:11841787

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

LIM and cysteine-rich domains 1

increases expression

Nitrofurantoin results in increased expression of LMCD1 mRNA

NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046

G

NFE2 like bZIP transcription factor 2

multiple interactions

NFE2L2 protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]; Nitrofurantoin results in increased expression of and affects the localization of NFE2L2 protein; POR protein affects the reaction [Nitrofurantoin results in increased expression of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NAD(P)H quinone dehydrogenase 1

increases response to substance
affects reduction

NQO1 protein results in increased susceptibility to Nitrofurantoin
NQO1 protein affects the reduction of Nitrofurantoin

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

orosomucoid 1

increases expression

Nitrofurantoin results in increased expression of ORM1 mRNA; Nitrofurantoin results in increased expression of ORM1 protein

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

cytochrome p450 oxidoreductase

increases metabolic processing
multiple interactions
affects metabolic processing

POR protein results in increased metabolism of Nitrofurantoin
POR protein affects the reaction [Nitrofurantoin results in increased expression of GCLC protein]; POR protein affects the reaction [Nitrofurantoin results in increased expression of NFE2L2 protein]
diphenyleneiodonium inhibits the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; Nitrofurantoin inhibits the reaction [POR protein results in increased metabolism of Misonidazole]

PMID:6802140 PMID:18206659 PMID:34021431

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

signal transducer and activator of transcription 1

multiple interactions

Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT1 protein]]

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 3

multiple interactions
increases activity
increases expression

Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; Rotenone promotes the reaction [Nitrofurantoin inhibits the reaction [CNTF protein results in increased phosphorylation of and results in increased activity of STAT3 protein]]
Nitrofurantoin results in increased activity of STAT3 protein
Nitrofurantoin results in increased expression of STAT3 mRNA

PMID:11841787 PMID:15748169

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

transforming growth factor, beta 2

increases expression

Nitrofurantoin results in increased expression of TGFB2 mRNA

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

phenytoin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aladin WD repeat nucleoporin

decreases expression

Phenytoin results in decreased expression of AAAS mRNA

NCBI chr 7:133,464,315...133,483,961
Ensembl chr 7:133,464,315...133,483,961

G

ATP binding cassette subfamily A member 1

decreases expression

Phenytoin results in decreased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 1A

affects response to substance
affects abundance
increases metabolic processing
decreases activity
increases transport
increases expression
multiple interactions

ABCB1 protein affects the susceptibility to Phenytoin
ABCB1 protein affects the abundance of Phenytoin
ABCB1 protein results in increased metabolism of Phenytoin
Phenytoin results in decreased activity of ABCB1 protein
ABCB1A protein results in increased transport of Phenytoin
Phenytoin results in increased expression of ABCB1 protein
Amino Acids, Peptides, and Proteins inhibits the reaction [Phenytoin results in increased expression of ABCB1 protein]; Phenytoin results in increased expression of and results in increased activity of ABCB1A protein

PMID:8001500 PMID:10580886 PMID:14749549 PMID:15569486 PMID:16220110 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

affects abundance

ABCB1B protein affects the abundance of Phenytoin

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily C member 1

multiple interactions
increases expression

KN 62 inhibits the reaction [Phenytoin results in increased expression of ABCC1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Phenytoin results in increased expression of ABCC1 protein]

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

affects transport
affects response to substance
increases expression
multiple interactions

ABCC2 protein affects the transport of Phenytoin
ABCC2 protein affects the susceptibility to Phenytoin
Phenytoin results in increased expression of ABCC2 protein
KN 62 inhibits the reaction [Phenytoin results in increased expression of ABCC2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Phenytoin results in increased expression of ABCC2 protein]

PMID:12663688 PMID:14636316 PMID:17376120 PMID:18473823

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression

Phenytoin results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 1

decreases expression

Phenytoin results in decreased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

abhydrolase domain containing 5, lysophosphatidic acid acyltransferase

increases expression

Phenytoin results in increased expression of ABHD5 mRNA

NCBI chr 8:122,000,241...122,026,447
Ensembl chr 8:122,000,389...122,026,447

G

actin-binding LIM protein 1

decreases expression

Phenytoin results in decreased expression of ABLIM1 mRNA

NCBI chr 1:256,083,747...256,372,075
Ensembl chr 1:256,084,297...256,371,969

G

angiotensin converting enzyme 2

decreases expression

Phenytoin results in decreased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acetylcholinesterase

increases activity

Phenytoin results in increased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

ADAM metallopeptidase domain 8

decreases expression

Phenytoin results in decreased expression of ADAM8 mRNA

NCBI chr 1:194,776,559...194,789,330
Ensembl chr 1:194,770,060...194,788,801

G

ADAM metallopeptidase with thrombospondin type 1 motif, 9

increases expression

Phenytoin results in increased expression of ADAMTS9 mRNA

NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929

G

adhesion G protein-coupled receptor B3

increases expression

Phenytoin results in increased expression of ADGRB3 mRNA

NCBI chr 9:27,421,168...28,148,979
Ensembl chr 9:27,421,168...28,148,855

G

adrenoceptor beta 3

decreases expression

Phenytoin results in decreased expression of ADRB3 mRNA

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

alpha-fetoprotein

decreases expression

Phenytoin results in decreased expression of AFP mRNA

PMID:14741686 PMID:26272751

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 3

decreases expression

Phenytoin results in decreased expression of AGAP3 mRNA

NCBI chr 4:10,674,746...10,724,848
Ensembl chr 4:10,674,064...10,725,244

G

aryl hydrocarbon receptor

multiple interactions
increases expression

CYP3A11 protein affects the reaction [Phenytoin results in increased expression of AHR mRNA]
Phenytoin results in increased expression of AHR protein
Ketoconazole inhibits the reaction [Phenytoin results in increased expression of AHR protein]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

A-kinase anchoring protein 10

increases expression

Phenytoin results in increased expression of AKAP10 mRNA

NCBI chr10:46,545,371...46,608,730
Ensembl chr10:46,551,532...46,608,769

G

aldo-keto reductase family 7 member A3

decreases expression
increases expression

Phenytoin results in decreased expression of AKR7A3 mRNA
Phenytoin results in increased expression of AKR7A3 mRNA

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

aldehyde dehydrogenase 1 family, member A1

increases expression

Phenytoin results in increased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 1 family, member A2

decreases expression

Phenytoin results in decreased expression of ALDH1A2 mRNA

NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107

G

antagonist of mitotic exit network 1 homolog

increases expression

Phenytoin results in increased expression of AMN1 mRNA

NCBI chr 4:182,155,140...182,182,085
Ensembl chr 4:182,155,142...182,182,016

G

annexin A4

increases expression

Phenytoin results in increased expression of ANXA4 mRNA

NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161

G

annexin A5

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA

NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369

G

apolipoprotein A1

increases expression

Phenytoin results in increased expression of APOA1 mRNA

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A4

increases expression

Phenytoin results in increased expression of APOA4 mRNA

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein E

increases expression

Phenytoin results in increased expression of APOE mRNA

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

androgen receptor

multiple interactions
increases activity
increases expression

[Phenytoin co-treated with Prednisolone] results in increased expression of AR protein
Phenytoin results in increased activity of AR protein
Phenytoin results in increased expression of AR mRNA; Phenytoin results in increased expression of AR protein
Ketoconazole inhibits the reaction [Phenytoin results in increased expression of AR protein]

PMID:19226368 PMID:19490052

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ADP-ribosylation factor interacting protein 1

increases expression

Phenytoin results in increased expression of ARFIP1 mRNA

NCBI chr 2:169,843,804...169,924,136
Ensembl chr 2:169,843,801...169,923,142

G

Rho GTPase activating protein 39

increases expression

Phenytoin results in increased expression of ARHGAP39 mRNA

NCBI chr 7:108,446,280...108,538,875
Ensembl chr 7:108,446,282...108,538,831

G

armadillo repeat containing 8

increases expression

Phenytoin results in increased expression of ARMC8 mRNA

NCBI chr 8:100,036,946...100,131,544
Ensembl chr 8:100,036,946...100,131,520

G

ATM serine/threonine kinase

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATP synthase mitochondrial F1 complex assembly factor 1

decreases expression

Phenytoin results in decreased expression of ATPAF1 mRNA

NCBI chr 5:129,265,789...129,292,463
Ensembl chr 5:129,266,404...129,293,556

G

beta-1,4-galactosyltransferase 7

decreases expression

Phenytoin results in decreased expression of B4GALT7 mRNA

NCBI chr17:9,018,514...9,027,591
Ensembl chr17:9,018,935...9,027,573

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

Phenytoin results in increased expression of and affects the localization of BCL2 protein
Phenytoin results in decreased expression of BCL2 mRNA

PMID:9118846 PMID:10695937

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

bone morphogenetic protein 1

decreases expression

Phenytoin results in decreased expression of BMP1 mRNA

NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776

G

bone morphogenetic protein 4

increases expression

Phenytoin results in increased expression of BMP4 mRNA

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

complement C2

decreases expression

Phenytoin results in decreased expression of C2 mRNA

NCBI chr20:3,951,474...3,970,376
Ensembl chr20:3,951,474...3,976,505

G

calcyclin binding protein

increases expression

Phenytoin results in increased expression of CACYBP mRNA

NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177

G

calcitonin-related polypeptide alpha

decreases expression

Phenytoin results in decreased expression of CALCA protein

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calmodulin 2

decreases expression

Phenytoin results in decreased expression of CALM2 mRNA

NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
Ensembl chr15:7,091,567...7,104,287

G

calpain 5

decreases expression

Phenytoin results in decreased expression of CAPN5 mRNA

NCBI chr 1:152,416,252...152,472,923
Ensembl chr 1:152,416,252...152,472,923

G

carbonic anhydrase 6

increases expression

Phenytoin results in increased expression of CAR6 mRNA

NCBI chr 5:160,658,104...160,676,644
Ensembl chr 5:160,658,105...160,676,644

G

CASK interacting protein 1

affects expression

Phenytoin affects the expression of CASKIN1 mRNA

NCBI chr10:13,512,684...13,533,380
Ensembl chr10:13,513,465...13,533,377

G

catalase

decreases response to substance

CAT protein results in decreased susceptibility to Phenytoin

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

Cbl proto-oncogene like 1

increases expression

Phenytoin results in increased expression of CBLL1 mRNA

NCBI chr 6:48,071,190...48,086,174
Ensembl chr 6:48,071,190...48,086,444

G

C-C motif chemokine ligand 2

increases expression

Phenytoin results in increased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin C

increases expression

Phenytoin results in increased expression of CCNC mRNA

NCBI chr 5:35,266,828...35,284,943
Ensembl chr 5:35,266,823...35,296,584

G

cyclin D1

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA
Phenytoin results in decreased expression of CCND1 mRNA

PMID:14741686 PMID:21224054

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin G1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

Cd47 molecule

decreases expression

Phenytoin results in decreased expression of CD47 mRNA

NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425

G

cadherin 2

decreases expression

Phenytoin results in decreased expression of CDH2 mRNA

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cyclin-dependent kinase 1

decreases expression

Phenytoin results in decreased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase inhibitor 1A

decreases expression
multiple interactions

Phenytoin results in decreased expression of CDKN1A mRNA
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein

PMID:14741686 PMID:21224054

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

caudal type homeo box 2

increases expression

Phenytoin results in increased expression of CDX2 mRNA

NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142

G

chymotrypsin like elastase 2A

decreases expression

Phenytoin results in decreased expression of CELA2A mRNA

NCBI chr 5:154,126,879...154,136,630
Ensembl chr 5:154,126,878...154,136,632

G

centrosomal protein 57

increases expression

Phenytoin results in increased expression of CEP57 mRNA

NCBI chr 8:10,669,588...10,689,257
Ensembl chr 8:10,669,590...10,689,249

G

cerberus 1, DAN family BMP antagonist

decreases expression

Phenytoin results in decreased expression of CER1 mRNA

NCBI chr 5:97,306,427...97,309,783
Ensembl chr 5:97,306,431...97,309,783

G

checkpoint kinase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

creatine kinase, M-type

increases expression

Phenytoin results in increased expression of CKM protein

NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720

G

chloride voltage-gated channel 6

decreases expression

Phenytoin results in decreased expression of CLCN6 mRNA

NCBI chr 5:158,434,299...158,465,174
Ensembl chr 5:158,434,299...158,465,059

G

cytidine/uridine monophosphate kinase 1

increases expression

Phenytoin results in increased expression of CMPK1 mRNA

NCBI chr 5:128,480,301...128,507,830
Ensembl chr 5:128,480,301...128,507,830

G

CCR4-NOT transcription complex, subunit 7

increases expression

Phenytoin results in increased expression of CNOT7 mRNA

NCBI chr16:51,775,416...51,794,581
Ensembl chr16:51,775,412...51,794,576

G

collagen type XI alpha 1 chain

increases expression

Phenytoin results in increased expression of COL11A1 mRNA

NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853

G

collagen type XVIII alpha 1 chain

decreases expression

Phenytoin results in decreased expression of COL18A1 mRNA

NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593

G

collagen type I alpha 1 chain

multiple interactions
decreases expression
increases expression

Phenytoin inhibits the reaction [IL1B protein results in decreased expression of COL1A1 mRNA]
Phenytoin results in decreased expression of COL1A1 mRNA
Phenytoin results in increased expression of COL1A1 mRNA

PMID:8971655 PMID:14741686

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

increases expression
affects expression

Phenytoin results in increased expression of COL1A2 mRNA
Phenytoin affects the expression of COL1A2 mRNA

PMID:14741686 PMID:24704097

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type VI alpha 1 chain

decreases expression
increases expression

Phenytoin results in decreased expression of COL6A1 mRNA
Phenytoin results in increased expression of COL6A1 mRNA

PMID:8224229 PMID:14741686

NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597

G

collagen type VI alpha 2 chain

increases expression

Phenytoin results in increased expression of COL6A2 mRNA

NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564

G

collagen type VI alpha 3 chain

increases expression

Phenytoin results in increased expression of COL6A3 mRNA

NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471

G

ceruloplasmin

decreases expression

Phenytoin results in decreased expression of CP mRNA

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

cleavage and polyadenylation specific factor 6

increases expression

Phenytoin results in increased expression of CPSF6 mRNA

NCBI chr 7:52,956,589...53,001,783
Ensembl chr 7:52,956,589...52,988,122

G

corticotropin releasing hormone

affects expression

Phenytoin affects the expression of CRH mRNA

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

CDP-L-ribitol pyrophosphorylase A

increases expression

Phenytoin results in increased expression of CRPPA mRNA

NCBI chr 6:53,120,264...53,397,030
Ensembl chr 6:53,121,438...53,397,028

G

cathepsin B

increases expression
decreases activity

Phenytoin results in increased expression of CTSB mRNA
Phenytoin results in decreased activity of CTSB protein

PMID:10914799 PMID:14741686

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin L

increases expression
decreases activity

Phenytoin results in increased expression of CTSL mRNA
Phenytoin results in decreased activity of CTSL protein

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cullin 4A

increases expression

Phenytoin results in increased expression of CUL4A mRNA

NCBI chr16:76,385,298...76,422,316
Ensembl chr16:76,384,546...76,422,330

G

C-X3-C motif chemokine ligand 1

increases expression

Phenytoin results in increased expression of CX3CL1 mRNA

NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833

G

C-X-C motif chemokine ligand 10

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 2

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; Alprostadil inhibits the reaction [[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

Phenytoin results in decreased activity of CYP19A1 protein

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

Phenytoin results in increased expression of CYP1A1 mRNA

PMID:9860486 PMID:17381134

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Phenytoin

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily b, polypeptide 1

decreases expression
increases expression

Phenytoin results in decreased expression of CYP2B1 mRNA
Phenytoin results in increased expression of CYP2B1 mRNA

PMID:9819145 PMID:10945841

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 2

increases expression

Phenytoin results in increased expression of CYP2B2 mRNA

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions
decreases expression
increases expression
increases activity

[Phenytoin results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]]]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]; NOC 18 inhibits the reaction [Phenytoin results in increased expression of CYP2B6 protein]; NR1I2 protein affects the reaction [Phenytoin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]; NR1I3 protein affects the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]; Phenytoin results in increased expression of and results in increased activity of CYP2B6 protein; pimagedine inhibits the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]
Phenytoin results in decreased expression of CYP2B10 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA
Phenytoin results in increased expression of CYP2B6 mRNA; Phenytoin results in increased expression of CYP2B6 protein
Phenytoin results in increased activity of CYP2B6 protein

PMID:12571232 PMID:12695351 PMID:14977870 PMID:15123723 PMID:17041008 More...

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions
decreases hydroxylation
increases metabolic processing
increases hydroxylation
decreases metabolic processing
affects metabolic processing
affects expression
increases expression

[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Phenytoin
CYP2C19 gene polymorphism results in decreased hydroxylation of Phenytoin
CYP2C19 protein results in increased metabolism of Phenytoin
CYP2C19 protein results in increased hydroxylation of Phenytoin
CYP2C19 gene polymorphism results in decreased metabolism of Phenytoin
CYP2C19 protein affects the metabolism of Phenytoin
Phenytoin affects the expression of CYP2C29 mRNA
Phenytoin results in increased expression of CYP2C protein; Phenytoin results in increased expression of CYP2C29 mRNA; Phenytoin results in increased expression of CYP2C29 protein
[Phenytoin results in decreased activity of CYP2C29 protein] which results in decreased reduction of and results in decreased oxidation of 9-anthraldehyde; NR1I3 protein affects the reaction [Phenytoin results in increased expression of CYP2C29 mRNA]

PMID:9146858 PMID:9333104 PMID:9579299 PMID:9860067 PMID:12051692 More...

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 7

increases metabolic processing

CYP2C9 protein results in increased metabolism of Phenytoin

NCBI chr 1:237,332,641...237,388,714
Ensembl chr 1:237,332,659...237,388,709

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Phenytoin

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
increases expression
decreases expression

NOC 18 inhibits the reaction [Phenytoin results in increased expression of CYP2E1 mRNA]
Phenytoin results in increased expression of CYP2E1 mRNA; Phenytoin results in increased expression of CYP2E1 protein
Phenytoin results in decreased expression of CYP2E1 mRNA

PMID:17381134 PMID:18206661

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
multiple interactions
increases activity

Phenytoin results in increased expression of CYP3A2 mRNA; Phenytoin results in increased expression of CYP3A2 protein
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Phenytoin; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Phenytoin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NOC 18 inhibits the reaction [Phenytoin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Phenytoin results in increased expression of CYP3A4 mRNA]; NR3C1 protein promotes the reaction [Phenytoin results in increased expression of CYP3A4 mRNA]; Phenytoin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Cholecalciferol]; Phenytoin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]
Phenytoin results in increased activity of CYP3A4 protein
Phenytoin results in increased expression of CYP3A4 mRNA; Phenytoin results in increased expression of CYP3A4 protein
Ketoconazole inhibits the reaction [Phenytoin results in increased expression of CYP3A2 protein]

PMID:9512926 PMID:10219967 PMID:12065438 PMID:12505310 PMID:12673034 More...

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

decreases expression
increases expression

Phenytoin results in decreased expression of CYP3A23-3A1 mRNA
Phenytoin results in increased expression of CYP3A23-3A1 mRNA

PMID:10945841 PMID:17381134

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

Phenytoin results in increased expression of CYP3A5 mRNA
Phenytoin results in increased expression of CYP3A13 mRNA

PMID:12673034 PMID:19903449

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 4, subfamily a, polypeptide 1

decreases expression

Phenytoin results in decreased expression of CYP4A1 mRNA

NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

increases expression

Phenytoin results in increased expression of CYP7B1 mRNA

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

death associated protein 3

increases expression

Phenytoin results in increased expression of DAP3 mRNA

NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461

G

death-associated protein kinase 2

decreases expression

Phenytoin results in decreased expression of DAPK2 mRNA

NCBI chr 8:66,706,536...66,825,567
Ensembl chr 8:66,706,609...66,825,567

G

DNA-damage inducible transcript 3

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DExH-box helicase 9

increases expression

Phenytoin results in increased expression of DHX9 mRNA

NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069

G

dematin actin binding protein

decreases expression

Phenytoin results in decreased expression of DMTN mRNA

NCBI chr15:45,677,974...45,702,261
Ensembl chr15:45,677,977...45,705,601

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA

NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967

G

E2F transcription factor 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

EBP like

increases expression

Phenytoin results in increased expression of EBPL mRNA

NCBI chr15:35,508,074...35,531,472
Ensembl chr15:35,508,074...35,531,472

G

early growth response 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 3

increases expression

Phenytoin results in increased expression of EGR3 mRNA

NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627

G

eukaryotic translation initiation factor 1A

increases expression

Phenytoin results in increased expression of EIF1A mRNA

NCBI chr18:39,325,695...39,338,043
Ensembl chr18:39,325,202...39,338,696

G

empty spiracles homeobox 2

decreases expression

Phenytoin results in decreased expression of EMX2 mRNA

NCBI chr 1:258,626,584...258,633,594
Ensembl chr 1:258,626,584...258,633,594

G

glutamyl aminopeptidase

decreases expression
increases expression

Phenytoin results in decreased expression of ENPEP mRNA
Phenytoin results in increased expression of ENPEP mRNA

NCBI chr 2:217,781,985...217,851,947
Ensembl chr 2:217,782,005...217,851,947

G

eomesodermin

increases expression

Phenytoin results in increased expression of EOMES mRNA

NCBI chr 8:118,181,340...118,189,186
Ensembl chr 8:118,181,777...118,188,316

G

epoxide hydrolase 1

affects response to substance
increases expression

EPHX1 gene polymorphism affects the susceptibility to Phenytoin
Phenytoin results in increased expression of EPHX1 mRNA

PMID:17381134 PMID:19952982

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

epoxide hydrolase 2

decreases expression

Phenytoin results in decreased expression of EPHX2 mRNA

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

G

estrogen receptor 1

increases expression

Phenytoin results in increased expression of ESR1 mRNA; Phenytoin results in increased expression of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

EYA transcriptional coactivator and phosphatase 1

decreases expression

Phenytoin results in decreased expression of EYA1 mRNA

NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483

G

coagulation factor X

decreases expression

Phenytoin results in decreased expression of F10 mRNA

NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141

G

coagulation factor II, thrombin

multiple interactions

[clobazam co-treated with Phenytoin] results in increased expression of [F2 protein binds to SERPINC1 protein]

NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486

G

Fas ligand

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FASL mRNA
Phenytoin results in decreased expression of FASL mRNA

PMID:21224054 PMID:23986454

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

F-box and leucine-rich repeat protein 3

increases expression

Phenytoin results in increased expression of FBXL3 mRNA

NCBI chr15:79,906,795...79,926,678
Ensembl chr15:79,906,795...79,927,867

G

F-box protein 30

increases expression

Phenytoin results in increased expression of FBXO30 mRNA

NCBI chr 1:5,655,341...5,671,558
Ensembl chr 1:5,655,339...5,672,441

G

fibroblast growth factor 12

increases expression

Phenytoin results in increased expression of FGF12 mRNA

NCBI chr11:71,997,151...72,564,757
Ensembl chr11:71,997,099...72,562,607

G

fibroblast growth factor 5

increases expression

Phenytoin results in increased expression of FGF5 mRNA

NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997

G

fibroblast growth factor 8

increases expression

Phenytoin results in increased expression of FGF8 mRNA

NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359

G

fibroblast growth factor 9

increases expression

Phenytoin results in increased expression of FGF9 mRNA

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

fibroblast growth factor receptor 2

increases expression

Phenytoin results in increased expression of FGFR2 mRNA; Phenytoin results in increased expression of FGFR2 protein

NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626

G

fibronectin leucine rich transmembrane protein 2

increases expression

Phenytoin results in increased expression of FLRT2 mRNA

NCBI chr 6:114,777,547...114,872,688
Ensembl chr 6:114,777,599...114,872,785

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

flavin containing dimethylaniline monoxygenase 4

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA

NCBI chr13:75,154,683...75,172,874
Ensembl chr13:75,154,684...75,172,874

G

fibromodulin

decreases expression

Phenytoin results in decreased expression of FMOD mRNA

NCBI chr13:45,493,517...45,504,134
Ensembl chr13:45,493,517...45,504,133

G

fragile X messenger ribonucleoprotein 1

increases expression

Phenytoin results in increased expression of FMR1 mRNA

NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050

G

fibronectin 1

increases expression

Phenytoin results in increased expression of FN1 mRNA

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

fibronectin type III domain containing 3a

increases expression

Phenytoin results in increased expression of FNDC3A mRNA

NCBI chr15:47,689,909...47,867,354
Ensembl chr15:47,689,919...47,866,784

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
decreases expression

[Phenytoin co-treated with Drugs, Chinese Herbal] inhibits the reaction [Kainic Acid results in increased expression of FOS mRNA]
Phenytoin results in decreased expression of FOS protein

PMID:7789465 PMID:8758711

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box C2

decreases expression

Phenytoin results in decreased expression of FOXC2 mRNA

NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737

G

forkhead box P3

multiple interactions
decreases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FOXP3 mRNA
Phenytoin results in decreased expression of FOXP3 mRNA

NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838

G

fibroblast growth factor receptor substrate 3

decreases expression

Phenytoin results in decreased expression of FRS3 mRNA

NCBI chr 9:13,288,559...13,297,285
Ensembl chr 9:13,288,667...13,295,382

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

Phenytoin results in decreased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glucose-6-phosphate dehydrogenase

affects response to substance

G6PDX protein affects the susceptibility to Phenytoin

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

GATA binding protein 3

multiple interactions
decreases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of GATA3 mRNA
Phenytoin results in decreased expression of GATA3 mRNA

NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391

G

glutamate cysteine ligase, modifier subunit

increases expression

Phenytoin results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glutamate-ammonia ligase

decreases activity

Phenytoin results in decreased activity of GLUL protein

NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108

G

G protein nucleolar 2

increases expression

Phenytoin results in increased expression of GNL2 mRNA

NCBI chr 5:137,293,141...137,318,528
Ensembl chr 5:137,293,081...137,318,526

G

glucosamine-6-phosphate deaminase 2

increases expression

Phenytoin results in increased expression of GNPDA2 mRNA

NCBI chr14:38,520,663...38,538,713
Ensembl chr14:38,520,705...38,538,713

G

glycoprotein m6a

increases expression

Phenytoin results in increased expression of GPM6A mRNA

NCBI chr16:36,641,282...36,973,377
Ensembl chr16:36,641,284...36,973,475

G

glutathione peroxidase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutamate ionotropic receptor NMDA type subunit 1

increases expression

Phenytoin results in increased expression of GRIN1 mRNA

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutathione S-transferase alpha 1

increases expression

Phenytoin results in increased expression of GSTA1 mRNA

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase alpha 2

increases expression
decreases expression

Phenytoin results in increased expression of GSTA2 mRNA
Phenytoin results in decreased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase kappa 1

decreases expression

Phenytoin results in decreased expression of GSTK1 mRNA

NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292

G

glutathione S-transferase mu 1

increases expression
multiple interactions

Phenytoin results in increased expression of GSTM1 mRNA
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein

PMID:17381134 PMID:21224054

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

increases expression

Phenytoin results in increased expression of GSTM2 mRNA

NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase, mu 5

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

glutathione S-transferase omega 1

decreases expression

Phenytoin results in decreased expression of GSTO1 mRNA

NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468

G

glucuronidase, beta

multiple interactions
decreases activity

Phenytoin inhibits the reaction [Misonidazole results in increased activity of GUSB protein]
Phenytoin results in decreased activity of GUSB protein

NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905

G

histone deacetylase 7

increases expression

Phenytoin results in increased expression of HDAC7 mRNA

NCBI chr 7:128,923,918...128,961,926
Ensembl chr 7:128,923,920...128,962,072

G

helicase with zinc finger

increases expression

Phenytoin results in increased expression of HELZ mRNA

NCBI chr10:92,479,403...92,645,234
Ensembl chr10:92,501,518...92,638,383

G

HEXIM P-TEFb complex subunit 1

increases expression

Phenytoin results in increased expression of HEXIM1 mRNA

NCBI chr10:88,062,808...88,064,920
Ensembl chr10:88,062,803...88,066,189

G

high mobility group box 1

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of HMGB1 protein

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heme oxygenase 1

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA
Phenytoin results in increased expression of HMOX1 mRNA

PMID:17381134 PMID:21224054

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heterogeneous nuclear ribonucleoprotein A2/B1

increases expression

Phenytoin results in increased expression of HNRNPA2B1 mRNA

NCBI chr 4:80,534,659...80,545,297
Ensembl chr 4:80,534,651...80,545,249

G

hook microtubule-tethering protein 3

increases expression

Phenytoin results in increased expression of HOOK3 mRNA

NCBI chr16:65,954,293...66,058,812
Ensembl chr16:65,954,350...66,061,338

G

homeobox A2

decreases expression

Phenytoin results in decreased expression of HOXA2 mRNA; Phenytoin results in decreased expression of HOXA2 protein

NCBI chr 4:81,262,668...81,266,970
Ensembl chr 4:81,262,768...81,265,044

G

homeo box B7

increases expression

Phenytoin results in increased expression of HOXB7 mRNA

NCBI chr10:81,252,616...81,256,034
Ensembl chr10:81,252,553...81,256,034

G

homeo box B9

increases expression

Phenytoin results in increased expression of HOXB9 mRNA

NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818

G

heat shock protein family A (Hsp70) member 1 like

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA

NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family B (small) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

heat shock protein family D (Hsp60) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA

NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662

G

heat shock protein family E (Hsp10) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA

NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089

G

interferon gamma

decreases expression

Phenytoin results in decreased expression of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interferon gamma receptor 1

increases expression

Phenytoin results in increased expression of IFNGR1 mRNA

NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785

G

interferon gamma receptor 2

increases expression

Phenytoin results in increased expression of IFNGR2 mRNA

NCBI chr11:30,779,733...30,798,005
Ensembl chr11:30,779,733...30,798,005

G

insulin-like growth factor 1

decreases expression

Phenytoin results in decreased expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

insulin-like growth factor 2

increases expression

Phenytoin results in increased expression of IGF2 mRNA

NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018

G

Indian hedgehog signaling molecule

increases expression

Phenytoin results in increased expression of IHH mRNA

NCBI chr 9:76,504,315...76,510,532
Ensembl chr 9:76,504,315...76,510,532

G

interleukin 17A

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL17A protein

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 18

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

Phenytoin inhibits the reaction [IL1B protein results in decreased expression of COL1A1 mRNA]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL1B mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL1B protein

PMID:8971655 PMID:21224054 PMID:23986454

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 23 subunit alpha

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL23A mRNA

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 6

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA
Phenytoin results in increased expression of IL6 mRNA

PMID:21224054 PMID:23986454

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 6 receptor

decreases expression

Phenytoin results in decreased expression of IL6RA mRNA

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

inositol polyphosphate-5-phosphatase F

increases expression

Phenytoin results in increased expression of INPP5F mRNA

NCBI chr 1:183,190,480...183,270,276
Ensembl chr 1:183,190,480...183,270,276

G

insulin receptor

increases expression

Phenytoin results in increased expression of INSR mRNA

NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883

G

intracisternal A particle-promoted polypeptide

increases expression

Phenytoin results in increased expression of IPP mRNA

NCBI chr 5:129,962,528...130,001,237
Ensembl chr 5:129,962,643...130,001,242

G

interferon regulatory factor 9

increases expression

Phenytoin results in increased expression of IRF9 mRNA

NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236

G

integrin subunit alpha 2

decreases expression

Phenytoin results in decreased expression of ITGA2 protein

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit alpha 8

increases expression

Phenytoin results in increased expression of ITGA8 mRNA

NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510

G

integrin subunit beta 1

decreases expression

Phenytoin results in decreased expression of ITGB1 protein

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

integrin subunit beta 3 binding protein

increases expression

Phenytoin results in increased expression of ITGB3BP mRNA

NCBI chr 5:114,460,217...114,525,538
Ensembl chr 5:114,460,221...114,525,704

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases expression

Phenytoin results in decreased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel subfamily D member 2

increases expression

Phenytoin results in increased expression of KCND2 mRNA

NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Phenytoin results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium channel tetramerization domain containing 3

increases expression

Phenytoin results in increased expression of KCTD3 mRNA

NCBI chr13:100,510,193...100,548,765
Ensembl chr13:100,510,195...100,548,718

G

kinase insert domain receptor

increases expression

Phenytoin results in increased expression of KDR mRNA

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

KH RNA binding domain containing, signal transduction associated 2

increases expression

Phenytoin results in increased expression of KHDRBS2 mRNA

NCBI chr 9:34,447,023...34,953,684
Ensembl chr 9:34,447,056...34,915,530

G

KLF transcription factor 2

increases expression

Phenytoin results in increased expression of KLF2 mRNA

NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944

G

kelch-like family member 2

increases expression

Phenytoin results in increased expression of KLHL2 mRNA

NCBI chr16:24,860,744...24,973,348
Ensembl chr16:24,860,667...24,973,341

G

kelch-like family member 7

increases expression

Phenytoin results in increased expression of KLHL7 mRNA

NCBI chr 4:11,006,366...11,055,399
Ensembl chr 4:11,006,375...11,055,541

G

KRIT1, ankyrin repeat containing

increases expression

Phenytoin results in increased expression of KRIT1 mRNA

NCBI chr 4:30,299,203...30,333,366
Ensembl chr 4:30,299,203...30,333,359

G

keratin 2

increases expression

Phenytoin results in increased expression of KRT2 mRNA

NCBI chr 7:132,940,879...132,948,031
Ensembl chr 7:132,940,862...132,947,963

G

kynurenine aminotransferase 1

increases activity

Phenytoin results in increased activity of KYAT1 protein

NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355

G

laminin subunit alpha 2

increases expression

Phenytoin results in increased expression of LAMA2 mRNA

NCBI chr 1:17,672,675...18,320,641
Ensembl chr 1:17,672,536...18,320,530

G

leucine aminopeptidase 3

affects expression

Phenytoin affects the expression of LAP3 mRNA

NCBI chr14:65,608,375...65,627,359
Ensembl chr14:65,608,376...65,627,359

G

lecithin cholesterol acyltransferase

increases expression

Phenytoin results in increased expression of LCAT mRNA

NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231

G

LIM domain binding 2

increases expression

Phenytoin results in increased expression of LDB2 mRNA

NCBI chr14:66,277,044...66,598,071
Ensembl chr14:66,277,085...66,597,778

G

lipin 1

increases expression

Phenytoin results in increased expression of LPIN1 mRNA

NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097

G

LPS responsive beige-like anchor protein

increases expression

Phenytoin results in increased expression of LRBA mRNA

NCBI chr 2:171,623,668...172,202,576
Ensembl chr 2:171,621,507...172,202,724

G

LSM1 homolog, mRNA degradation associated

decreases expression

Phenytoin results in decreased expression of LSM1 mRNA

NCBI chr16:66,277,345...66,288,852
Ensembl chr16:66,277,345...66,288,852

G

latent transforming growth factor beta binding protein 4

increases expression

Phenytoin results in increased expression of LTBP4 mRNA

NCBI chr 1:82,600,136...82,634,346
Ensembl chr 1:82,600,136...82,632,178

G

lysophospholipase 1

increases expression

Phenytoin results in increased expression of LYPLA1 mRNA

NCBI chr 5:14,679,605...14,708,774
Ensembl chr 5:14,679,606...14,708,746

G

microtubule-associated protein 1B

increases expression

Phenytoin results in increased expression of MAP1B mRNA

NCBI chr 2:30,817,261...30,910,458
Ensembl chr 2:30,817,261...30,910,317

G

mitogen activated protein kinase kinase kinase 4

increases expression

Phenytoin results in increased expression of MAP3K4 mRNA

NCBI chr 1:48,431,801...48,519,358
Ensembl chr 1:48,431,830...48,519,358

G

mitogen activated protein kinase 1

decreases phosphorylation

Phenytoin results in decreased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation

Phenytoin results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

microtubule-associated protein, RP/EB family, member 3

increases expression

Phenytoin results in increased expression of MAPRE3 mRNA

NCBI chr 6:25,513,800...25,558,876
Ensembl chr 6:25,513,800...25,558,881

G

mannose binding lectin 1

decreases expression

Phenytoin results in decreased expression of MBL1 mRNA

NCBI chr16:17,029,146...17,035,187
Ensembl chr16:17,029,118...17,035,174

G

midkine

increases expression

Phenytoin results in increased expression of MDK mRNA

NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130

G

MDM2 proto-oncogene

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

malic enzyme 1

increases expression

Phenytoin results in increased expression of ME1 mRNA

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

mesenchyme homeobox 1

decreases expression

Phenytoin results in decreased expression of MEOX1 mRNA

NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660

G

mesoderm posterior bHLH transcription factor 1

increases expression

Phenytoin results in increased expression of MESP1 mRNA

NCBI chr 1:133,738,357...133,739,875
Ensembl chr 1:133,738,357...133,739,875

G

mex-3 RNA binding family member D

increases expression

Phenytoin results in increased expression of MEX3D mRNA

NCBI chr 7:9,325,575...9,332,705
Ensembl chr 7:9,325,488...9,332,096

G

alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

increases expression

Phenytoin results in increased expression of MGAT2 mRNA

NCBI chr 6:87,656,360...87,658,849
Ensembl chr 6:87,656,349...87,658,177

G

O-6-methylguanine-DNA methyltransferase

increases methylation

Phenytoin results in increased methylation of MGMT promoter

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

marker of proliferation Ki-67

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 1

decreases expression
increases expression

Phenytoin results in decreased expression of MMP1 mRNA
Phenytoin results in increased expression of MMP1 mRNA

PMID:10914799 PMID:14741686 PMID:15948689

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 2

decreases expression

Phenytoin results in decreased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

decreases expression

Phenytoin results in decreased expression of MMP3 mRNA

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

mitochondrial ribosomal protein S18C

increases expression

Phenytoin results in increased expression of MRPS18C mRNA

NCBI chr14:8,812,301...8,818,538
Ensembl chr14:8,791,330...8,818,516

G

metal response element binding transcription factor 2

increases expression

Phenytoin results in increased expression of MTF2 mRNA

NCBI chr14:1,639,256...1,683,513
Ensembl chr14:1,640,746...1,683,524

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like

increases expression

Phenytoin results in increased expression of MTHFD1L mRNA

NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905

G

metaxin 2

increases expression

Phenytoin results in increased expression of MTX2 mRNA

NCBI chr 3:59,730,206...59,792,202
Ensembl chr 3:59,730,197...59,792,201

G

MYC proto-oncogene, bHLH transcription factor

increases expression
decreases expression

Phenytoin results in increased expression of MYC protein
Phenytoin results in decreased expression of MYC mRNA

PMID:10695937 PMID:26272751

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

myosin IE

increases expression

Phenytoin results in increased expression of MYO1E mRNA

NCBI chr 8:70,887,934...71,080,180
Ensembl chr 8:70,887,870...71,080,169

G

nucleosome assembly protein 1-like 2

affects expression

Phenytoin affects the expression of NAP1L2 mRNA

NCBI chr X:68,174,051...68,176,449
Ensembl chr X:68,173,987...68,176,666

G

neurocan

increases expression

Phenytoin results in increased expression of NCAN mRNA

NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436

G

nucleolin

decreases expression

Phenytoin results in decreased expression of NCL mRNA

NCBI chr 9:86,999,588...87,008,112
Ensembl chr 9:86,998,019...87,008,136

G

nuclear receptor coactivator 1

multiple interactions

Phenytoin promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein]

NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664

G

negative elongation factor complex member A

decreases expression

Phenytoin results in decreased expression of NELFA mRNA

NCBI chr14:76,808,920...76,832,998
Ensembl chr14:76,808,870...76,832,994

G

nestin

decreases expression

Phenytoin results in decreased expression of NES mRNA

NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777

G

neurogenin 2

increases expression

Phenytoin results in increased expression of NEUROG2 mRNA

NCBI chr 2:216,092,709...216,095,276
Ensembl chr 2:216,093,363...216,094,154

G

nuclear factor kappa B subunit 1

multiple interactions
increases expression

Phenytoin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased localization of and results in increased activity of NFKB1 protein]
Phenytoin results in increased expression of NFKB1 mRNA

PMID:10700573 PMID:14741686

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

decreases degradation

Phenytoin results in decreased degradation of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

N-glycanase 1

increases expression

Phenytoin results in increased expression of NGLY1 mRNA

NCBI chr15:9,153,738...9,210,228
Ensembl chr15:9,153,738...9,204,630

G

NLR family, pyrin domain containing 3

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of NLRP3 mRNA

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neuronal PAS domain protein 2

increases expression

Phenytoin results in increased expression of NPAS2 mRNA

NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320

G

NAD(P)H quinone dehydrogenase 1

increases expression

Phenytoin results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
increases activity
increases expression
affects activity

Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]]]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Phenytoin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1I2 protein affects the reaction [Phenytoin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein affects the reaction [Phenytoin results in increased expression of CYP2C9 mRNA]; NR1I2 protein affects the reaction [Phenytoin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]; Phenytoin binds to and results in increased activity of NR1I2 protein; Phenytoin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]
Phenytoin results in increased activity of NR1I2 protein
Phenytoin results in increased expression of NR1I2 protein
Phenytoin affects the activity of NR1I2 protein

PMID:12065438 PMID:12695340 PMID:12695351 PMID:14600250 PMID:14977870 More...

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions
increases localization
increases activity
increases expression

[Phenytoin results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; NR1I3 protein affects the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]; Phenytoin promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein]
Phenytoin results in increased localization of NR1I3 protein
NR1I3 protein affects the reaction [Phenytoin results in increased expression of CYP2C29 mRNA]; NR1I3 protein affects the reaction [Phenytoin results in increased expression of CYP2C37 mRNA]
Phenytoin results in increased expression of NR1I3 protein

PMID:15123723 PMID:15155833 PMID:15849716 PMID:16936065 PMID:17041008 More...

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor subfamily 2, group F, member 1

increases expression

Phenytoin results in increased expression of NR2F1 mRNA

NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
increases expression

Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Phenytoin results in increased expression of CYP2B6 mRNA]]]; NR3C1 protein promotes the reaction [Phenytoin results in increased expression of CYP3A4 mRNA]
Phenytoin results in increased expression of NR3C1 mRNA

PMID:10219967 PMID:12695351 PMID:20345932

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

neuronal cell adhesion molecule

decreases expression

Phenytoin results in decreased expression of NRCAM mRNA

NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992

G

NSE3 homolog, SMC5-SMC6 complex component

increases expression

Phenytoin results in increased expression of NSMCE3 mRNA

NCBI chr 1:118,401,302...118,402,629

G

5'-nucleotidase domain containing 1

increases expression

Phenytoin results in increased expression of NT5DC1 mRNA

NCBI chr20:38,105,677...38,208,613
Ensembl chr20:38,105,678...38,208,591

G

neurotrophin 3

decreases expression

Phenytoin results in decreased expression of NTF3 mRNA

NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596

G

nucleoporin 153

increases expression

Phenytoin results in increased expression of NUP153 mRNA

NCBI chr17:17,972,217...18,024,876
Ensembl chr17:17,972,217...18,024,876

G

oligodendrocyte transcription factor 3

increases expression

Phenytoin results in increased expression of OLIG3 mRNA

NCBI chr 1:14,081,259...14,083,336
Ensembl chr 1:14,081,328...14,082,149

G

opioid receptor, mu 1

multiple interactions

[cyprodime binds to and results in decreased activity of OPRM1 protein] which results in decreased susceptibility to Phenytoin

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

platelet-activating factor acetylhydrolase 1b, regulatory subunit 1

decreases expression

Phenytoin results in decreased expression of PAFAH1B1 mRNA

NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808

G

platelet-activating factor acetylhydrolase 1b, catalytic subunit 2

decreases expression

Phenytoin results in decreased expression of PAFAH1B2 mRNA

NCBI chr 8:46,260,069...46,312,073
Ensembl chr 8:46,261,064...46,279,833

G

par-6 family cell polarity regulator gamma

increases expression

Phenytoin results in increased expression of PARD6G mRNA

NCBI chr18:73,497,992...73,565,048
Ensembl chr18:73,498,021...73,565,029

G

poly (ADP-ribose) glycohydrolase

increases expression

Phenytoin results in increased expression of PARG mRNA

NCBI chr16:7,436,429...7,544,276
Ensembl chr16:7,436,476...7,544,273

G

paired box 3

decreases expression

Phenytoin results in decreased expression of PAX3 mRNA

PMID:9118846 PMID:31711903

NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042

G

paired box 6

increases expression

Phenytoin results in increased expression of PAX6 mRNA

NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014

G

PBX homeobox 1

increases expression

Phenytoin results in increased expression of PBX1 mRNA

NCBI chr13:80,278,766...80,588,563
Ensembl chr13:80,278,770...80,588,594

G

prenylcysteine oxidase 1

increases expression

Phenytoin results in increased expression of PCYOX1 mRNA

NCBI chr 4:118,832,114...118,842,951
Ensembl chr 4:118,830,638...118,842,951

G

platelet derived growth factor subunit A

increases expression

Phenytoin results in increased expression of PDGFA mRNA

NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497

G

platelet derived growth factor subunit B

increases expression

Phenytoin results in increased expression of PDGFB mRNA; Phenytoin results in increased expression of PDGFB protein

PMID:8463938 PMID:9029455 PMID:14741686

NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984

G

progesterone receptor membrane component 1

increases expression

Phenytoin results in increased expression of PGRMC1 mRNA

NCBI chr X:115,832,865...115,841,060
Ensembl chr X:115,832,884...115,888,682

G

PHD finger protein 14

increases expression

Phenytoin results in increased expression of PHF14 mRNA

NCBI chr 4:40,009,691...40,195,877
Ensembl chr 4:40,009,264...40,195,885

G

phosphatidylinositol-5-phosphate 4-kinase type 2 alpha

increases expression

Phenytoin results in increased expression of PIP4K2A mRNA

NCBI chr17:81,496,669...81,668,180
Ensembl chr17:81,496,670...81,668,029

G

plasminogen activator, urokinase receptor

decreases expression

Phenytoin results in decreased expression of PLAUR mRNA

NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595

G

phospholipase C-like 1

increases expression

Phenytoin results in increased expression of PLCL1 mRNA

NCBI chr 9:56,901,573...57,238,782
Ensembl chr 9:56,901,534...57,238,782

G

plectin

increases expression

Phenytoin results in increased expression of PLEC mRNA

NCBI chr 7:107,887,764...107,949,100
Ensembl chr 7:107,887,764...107,945,467

G

phospholipid transfer protein

increases expression

Phenytoin results in increased expression of PLTP mRNA

NCBI chr 3:153,574,825...153,592,647
Ensembl chr 3:153,574,825...153,592,647

G

plexin B2

decreases expression

Phenytoin results in decreased expression of PLXNB2 mRNA

NCBI chr 7:120,232,276...120,258,385
Ensembl chr 7:120,232,331...120,258,330

G

pinin, desmosome associated protein

increases expression

Phenytoin results in increased expression of PNN mRNA

NCBI chr 6:76,758,138...76,766,451
Ensembl chr 6:76,758,117...76,766,889

G

paraoxonase 1

decreases expression
affects activity

Phenytoin results in decreased expression of PON1 mRNA
Phenytoin affects the activity of PON1 protein

PMID:15136057 PMID:28032682

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

cytochrome p450 oxidoreductase

increases activity

Phenytoin results in increased activity of POR protein

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

POU class 3 homeobox 1

increases expression

Phenytoin results in increased expression of POU3F1 protein

NCBI chr 5:136,910,391...136,913,371
Ensembl chr 5:136,910,391...136,913,371

G

peptidylprolyl isomerase like 4

increases expression

Phenytoin results in increased expression of PPIL4 mRNA

NCBI chr 1:2,273,582...2,305,639
Ensembl chr 1:2,273,609...2,305,632

G

protein kinase, DNA-activated, catalytic subunit

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A14 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA; PRKDC gene mutant form results in increased susceptibility to [Rifampin co-treated with Phenytoin co-treated with Monocrotaline]

NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952

G

prolactin

decreases expression

Phenytoin results in decreased expression of PRL mRNA; Phenytoin results in decreased expression of PRL protein

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

protein arginine methyltransferase 3

increases expression

Phenytoin results in increased expression of PRMT3 mRNA

NCBI chr 1:99,492,712...99,581,774
Ensembl chr 1:99,492,724...99,579,435

G

serine protease 12

increases expression

Phenytoin results in increased expression of PRSS12 mRNA

NCBI chr 2:211,624,134...211,684,126
Ensembl chr 2:211,624,134...211,684,126

G

PC4 and SRSF1 interacting protein 1

increases expression

Phenytoin results in increased expression of PSIP1 mRNA

NCBI chr 5:97,847,010...97,879,280
Ensembl chr 5:97,847,015...97,879,257

G

proteasome 26S subunit, ATPase 6

increases expression

Phenytoin results in increased expression of PSMC6 mRNA

NCBI chr15:18,542,585...18,564,057
Ensembl chr15:18,542,563...18,564,055

G

proteasome 26S subunit, non-ATPase 12

increases expression

Phenytoin results in increased expression of PSMD12 mRNA

NCBI chr10:92,438,223...92,457,323
Ensembl chr10:92,438,298...92,457,287

G

polypyrimidine tract binding protein 2

increases expression

Phenytoin results in increased expression of PTBP2 mRNA

NCBI chr 2:207,812,659...207,874,019
Ensembl chr 2:207,812,920...207,873,506

G

patched 1

increases expression

Phenytoin results in increased expression of PTCH1 mRNA

NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333

G

prostaglandin-endoperoxide synthase 2

increases expression

Phenytoin results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

parathyroid hormone

increases expression

Phenytoin results in increased expression of PTH protein

NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530

G

RAD50 double strand break repair protein

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA

NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396

G

retinoic acid induced 1

increases expression

Phenytoin results in increased expression of RAI1 mRNA

NCBI chr10:44,913,231...45,008,232
Ensembl chr10:44,947,909...45,008,232

G

RAN binding protein 6

increases expression

Phenytoin results in increased expression of RANBP6 mRNA

NCBI chr 1:227,572,394...227,576,915
Ensembl chr 1:227,572,105...227,576,942

G

Rap guanine nucleotide exchange factor 4

increases expression

Phenytoin results in increased expression of RAPGEF4 mRNA

NCBI chr 3:56,809,388...57,101,332
Ensembl chr 3:56,809,270...57,102,316

G

retinoic acid receptor, alpha

increases expression
decreases expression

Phenytoin results in increased expression of RARA mRNA
Phenytoin results in decreased expression of RARA mRNA

PMID:9118846 PMID:9988880

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

retinoic acid receptor, beta

increases expression

Phenytoin results in increased expression of RARB mRNA

NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288

G

retinoic acid receptor, gamma

increases expression

Phenytoin results in increased expression of RARG mRNA

NCBI chr 7:133,367,833...133,390,301
Ensembl chr 7:133,367,833...133,390,177

G

RNA binding motif protein 12

increases expression

Phenytoin results in increased expression of RBM12 mRNA

NCBI chr 3:144,609,661...144,629,911
Ensembl chr 3:144,611,623...144,629,915
Ensembl chr 3:144,611,623...144,629,915

G

RNA binding motif protein 3

increases expression

Phenytoin results in increased expression of RBM3 mRNA

NCBI chr X:14,348,909...14,352,387
Ensembl chr X:14,348,910...14,353,580

G

RNA binding motif protein 34

increases expression

Phenytoin results in increased expression of RBM34 mRNA

NCBI chr19:54,936,516...54,956,810
Ensembl chr19:54,936,531...54,956,715

G

retinol binding protein 2

increases expression

Phenytoin results in increased expression of RBP2 mRNA

NCBI chr 8:99,079,293...99,104,489
Ensembl chr 8:99,079,104...99,104,473

G

retinol dehydrogenase 14

increases expression

Phenytoin results in increased expression of RDH14 mRNA

NCBI chr 6:33,156,569...33,161,712
Ensembl chr 6:33,156,569...33,161,712

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases activity

Phenytoin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased localization of and results in increased activity of RELA protein]
Phenytoin results in increased activity of RELA protein

PMID:10700573 PMID:15322231

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ras homolog family member A

decreases expression

Phenytoin results in decreased expression of RHOA mRNA

NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746

G

RIO kinase 2

increases expression

Phenytoin results in increased expression of RIOK2 mRNA

NCBI chr 1:58,103,132...58,119,397
Ensembl chr 1:58,103,084...58,120,512

G

ribonuclease H1

decreases expression

Phenytoin results in decreased expression of RNASEH1 mRNA

NCBI chr 6:45,282,849...45,292,258
Ensembl chr 6:45,282,854...45,292,236

G

Rho family GTPase 1

increases expression

Phenytoin results in increased expression of RND1 mRNA

NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399

G

ring finger protein 115

increases expression

Phenytoin results in increased expression of RNF115 mRNA

NCBI chr 2:184,262,087...184,329,839
Ensembl chr 2:184,262,371...184,329,823

G

ribulose-5-phosphate-3-epimerase

increases expression

Phenytoin results in increased expression of RPE mRNA

NCBI chr 9:68,191,027...68,211,295
Ensembl chr 9:68,191,292...68,211,591

G

ribosomal protein L28

increases expression

Phenytoin results in increased expression of RPL28 mRNA

NCBI chr 1:69,052,148...69,054,735
Ensembl chr 1:69,053,203...69,055,032

G

ribosomal protein S6 kinase A3

increases expression

Phenytoin results in increased expression of RPS6KA3 mRNA

NCBI chr X:35,517,306...35,623,296
Ensembl chr X:35,517,306...35,623,207

G

ribosomal protein SA

increases expression

Phenytoin results in increased expression of RPSA mRNA

NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247

G

arginine and serine rich coiled-coil 1

decreases expression

Phenytoin results in decreased expression of RSRC1 mRNA

NCBI chr 2:151,226,821...151,632,771
Ensembl chr 2:151,231,156...151,632,765

G

ryanodine receptor 2

increases expression

Phenytoin results in increased expression of RYR2 mRNA

NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142

G

S100 calcium binding protein A10

increases expression

Phenytoin results in increased expression of S100A10 mRNA

NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661

G

S100 calcium-binding protein A4

increases expression

Phenytoin results in increased expression of S100A4 mRNA

NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254

G

S100 calcium binding protein A8

multiple interactions

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

multiple interactions
increases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA
Phenytoin results in increased expression of S100A9 mRNA

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

spliceosome associated factor 3, U4/U6 recycling protein

increases expression

Phenytoin results in increased expression of SART3 mRNA

NCBI chr12:42,859,026...42,887,041
Ensembl chr12:42,859,305...42,887,038

G

sterol-C5-desaturase

increases expression

Phenytoin results in increased expression of SC5D mRNA

NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273

G

SR-related CTD-associated factor 1

increases expression

Phenytoin results in increased expression of SCAF1 mRNA

NCBI chr 1:95,485,448...95,499,389
Ensembl chr 1:95,485,448...95,496,029

G

scavenger receptor class B, member 1

decreases expression

Phenytoin results in decreased expression of SCARB1 mRNA

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

sodium voltage-gated channel alpha subunit 1

affects response to substance

SCN1A gene polymorphism affects the susceptibility to Phenytoin; SCN1A protein affects the susceptibility to Phenytoin

PMID:15805193 PMID:17001291

NCBI chr 3:50,952,790...51,071,804
Ensembl chr 3:50,952,791...51,071,699

G

sodium voltage-gated channel beta subunit 1

affects binding
multiple interactions
decreases response to substance

Phenytoin binds to [SCN1B protein binds to SCN3A protein]
Phenytoin results in decreased activity of [SCN1B protein binds to SCN3A protein]
SCN1B protein mutant form results in decreased susceptibility to Phenytoin

NCBI chr 1:86,353,917...86,363,820
Ensembl chr 1:86,353,917...86,363,739

G

sodium voltage-gated channel alpha subunit 2

decreases activity

Phenytoin results in decreased activity of SCN2A protein

NCBI chr 3:50,302,781...50,437,504
Ensembl chr 3:50,302,877...50,437,214

G

sodium voltage-gated channel alpha subunit 3

multiple interactions
affects binding

Phenytoin results in decreased activity of [SCN1B protein binds to SCN3A protein]
Phenytoin binds to [SCN1B protein binds to SCN3A protein]

NCBI chr 3:50,146,411...50,258,119
Ensembl chr 3:50,148,139...50,258,119

G

syndecan 4

decreases expression

Phenytoin results in decreased expression of SDC4 mRNA

NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580

G

selectin E

multiple interactions

[clobazam co-treated with Phenytoin] results in increased expression of SELE protein

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

SUMO specific peptidase 7

increases expression

Phenytoin results in increased expression of SENP7 mRNA

NCBI chr11:44,423,733...44,584,129
Ensembl chr11:44,423,735...44,564,711

G

serpin family C member 1

multiple interactions

[clobazam co-treated with Phenytoin] results in increased expression of [F2 protein binds to SERPINC1 protein]

NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293

G

serpin family E member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

SH3 and SYLF domain containing 1

increases expression

Phenytoin results in increased expression of SH3YL1 mRNA

NCBI chr 6:47,522,098...47,565,858
Ensembl chr 6:47,522,091...47,565,858

G

sonic hedgehog signaling molecule

increases expression

Phenytoin results in increased expression of SHH mRNA

NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170

G

siah E3 ubiquitin protein ligase 1

increases expression

Phenytoin results in increased expression of SIAH1A mRNA

NCBI chr19:20,378,908...20,402,512
Ensembl chr19:20,378,439...20,403,808

G

signal-induced proliferation-associated 1 like 1

increases expression

Phenytoin results in increased expression of SIPA1L1 mRNA

NCBI chr 6:101,839,351...102,118,408
Ensembl chr 6:101,839,404...102,116,950

G

solute carrier family 22 member 7

decreases expression

Phenytoin results in decreased expression of SLC22A7 mRNA

NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921

G

solute carrier family 4 member 3

increases expression

Phenytoin results in increased expression of SLC4A3 mRNA

NCBI chr 9:77,036,243...77,053,940
Ensembl chr 9:77,037,016...77,049,105

G

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1

increases expression

Phenytoin results in increased expression of SMARCA1 mRNA

NCBI chr X:126,980,201...127,066,385
Ensembl chr X:126,994,947...127,066,347

G

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5

increases expression

Phenytoin results in increased expression of SMARCA5 mRNA

NCBI chr19:27,271,918...27,304,594
Ensembl chr19:27,271,148...27,304,594

G

structural maintenance of chromosomes 2

increases expression

Phenytoin results in increased expression of SMC2 mRNA

NCBI chr 5:66,806,882...66,853,478
Ensembl chr 5:66,807,011...66,853,242

G

structural maintenance of chromosomes 3

increases expression

Phenytoin results in increased expression of SMC3 mRNA

NCBI chr 1:252,601,422...252,644,522
Ensembl chr 1:252,601,753...252,644,522

G

structural maintenance of chromosomes 5

increases expression

Phenytoin results in increased expression of SMC5 mRNA

NCBI chr 1:220,769,366...220,839,138
Ensembl chr 1:220,769,366...220,839,096

G

sorting nexin 2

increases expression

Phenytoin results in increased expression of SNX2 mRNA

NCBI chr18:46,602,223...46,643,870
Ensembl chr18:46,602,284...46,643,865

G

Sp3 transcription factor

increases expression

Phenytoin results in increased expression of SP3 mRNA

NCBI chr 3:57,811,855...57,857,150
Ensembl chr 3:57,812,075...57,860,342

G

ST13, Hsp70 interacting protein

increases expression

Phenytoin results in increased expression of ST13 mRNA

NCBI chr 7:112,891,007...112,925,727
Ensembl chr 7:112,844,375...112,925,945

G

signal transducer and activator of transcription 4

decreases expression

Phenytoin results in decreased expression of STAT4 mRNA

NCBI chr 9:49,472,660...49,588,540
Ensembl chr 9:49,419,340...49,588,540

G

sulfotransferase family 1A member 1

decreases expression

Phenytoin results in decreased expression of SULT1A1 mRNA

PMID:9566755 PMID:17381134

NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562

G

sulfotransferase family 2A member 1

decreases expression

Phenytoin results in decreased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

synapsin I

multiple interactions
decreases expression

Thyroxine inhibits the reaction [Phenytoin results in decreased expression of SYN1 mRNA]

NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396

G

synaptophysin

multiple interactions
decreases expression

Thyroxine inhibits the reaction [Phenytoin results in decreased expression of SYP mRNA]

NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745

G

synaptophysin-like 1

increases expression

Phenytoin results in increased expression of SYPL1 mRNA

NCBI chr 6:49,565,111...49,585,205
Ensembl chr 6:49,565,154...49,585,330

G

TATA-box binding protein associated factor 9b

increases expression

Phenytoin results in increased expression of TAF9B mRNA

NCBI chr X:71,289,290...71,300,142
Ensembl chr X:71,289,290...71,300,604

G

T-box transcription factor 21

multiple interactions
decreases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TBX21 mRNA
Phenytoin results in decreased expression of TBX21 mRNA

NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831

G

transcription elongation factor A like 1

increases expression

Phenytoin results in increased expression of TCEAL1 mRNA

NCBI chr X:100,058,485...100,060,439
Ensembl chr X:100,058,132...100,060,551

G

transcription factor 15

decreases expression

Phenytoin results in decreased expression of TCF15 mRNA

NCBI chr 3:140,638,984...140,644,766
Ensembl chr 3:140,638,984...140,644,766

G

telomeric repeat binding factor 1

increases expression

Phenytoin results in increased expression of TERF1 mRNA

NCBI chr 5:3,443,103...3,472,377
Ensembl chr 5:3,443,106...3,472,340

G

transforming growth factor alpha

increases expression

Phenytoin results in increased expression of TGFA mRNA

NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894

G

transforming growth factor, beta 1

increases expression
decreases expression

Phenytoin results in increased expression of TGFB1 mRNA
Phenytoin results in decreased expression of TGFB1 mRNA

PMID:7841657 PMID:9988880 PMID:16141649

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta 2

decreases expression

Phenytoin results in decreased expression of TGFB2 mRNA

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

transforming growth factor, beta 3

increases expression

Phenytoin results in increased expression of TGFB3 mRNA

NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564

G

THO complex subunit 6

decreases expression

Phenytoin results in decreased expression of THOC6 mRNA

NCBI chr10:12,700,051...12,705,411
Ensembl chr10:12,700,051...12,706,925

G

TIMP metallopeptidase inhibitor 1

increases expression

Phenytoin results in increased expression of TIMP1 mRNA; Phenytoin results in increased expression of TIMP1 protein

PMID:10914799 PMID:14741686 PMID:15948689

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

transketolase

increases expression

Phenytoin results in increased expression of TKT mRNA

NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698

G

toll-like receptor 2

multiple interactions
increases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of TLR2 mRNA
Phenytoin results in increased expression of TLR2 mRNA

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

toll-like receptor 4

multiple interactions
decreases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR4 mRNA
Phenytoin results in decreased expression of TLR4 mRNA

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

toll-like receptor 9

multiple interactions
decreases expression

[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR9 mRNA
Phenytoin results in decreased expression of TLR9 mRNA

NCBI chr 8:106,864,680...106,868,796
Ensembl chr 8:106,864,680...106,868,796

G

tumor necrosis factor

increases expression

Phenytoin results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 10

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

tumor protein p53

increases expression

Phenytoin results in increased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tumor protein p53 binding protein, 2

increases expression

Phenytoin results in increased expression of TRP53BP2 mRNA

NCBI chr13:94,088,769...94,145,436
Ensembl chr13:94,088,709...94,145,432

G

TNFRSF1A-associated via death domain

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA

NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638

G

tRNA methyltransferase 10B

increases expression

Phenytoin results in increased expression of TRMT10B mRNA

NCBI chr 5:59,548,845...59,572,529
Ensembl chr 5:59,548,869...59,572,526

G

terminal uridylyl transferase 4

increases expression

Phenytoin results in increased expression of TUT4 mRNA

NCBI chr 5:123,201,723...123,306,582
Ensembl chr 5:123,203,003...123,306,465

G

thioredoxin reductase 1

increases expression

Phenytoin results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

ubiquitin-conjugating enzyme E2D 2

increases expression

Phenytoin results in increased expression of UBE2D2 mRNA

NCBI chr18:27,364,325...27,406,322
Ensembl chr18:27,364,303...27,406,181

G

ubiquitin-like 5

decreases expression

Phenytoin results in decreased expression of UBL5 mRNA

NCBI chr 8:19,181,504...19,185,224
Ensembl chr 8:19,181,615...19,185,217

G

ubiquitin protein ligase E3 component n-recognin 1

increases expression

Phenytoin results in increased expression of UBR1 mRNA

NCBI chr 3:107,813,721...107,921,701
Ensembl chr 3:107,811,392...107,922,204

G

UDP-glucose 6-dehydrogenase

decreases expression

Phenytoin results in decreased expression of UGDH mRNA

NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354

G

UDP glucuronosyltransferase family 1 member A1

affects expression
increases expression
multiple interactions
increases activity

Phenytoin affects the expression of UGT1A1 mRNA
Phenytoin results in increased expression of UGT1A1 mRNA; Phenytoin results in increased expression of UGT1A1 protein
Phenytoin results in increased expression of and results in increased activity of UGT1A1 protein
Phenytoin results in increased activity of UGT1A1 protein

PMID:10421657 PMID:15849716 PMID:17381134 PMID:27413119

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A6

increases expression

Phenytoin results in increased expression of UGT1A6 mRNA

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 2 family, polypeptide B1

increases expression

Phenytoin results in increased expression of UGT2B1 mRNA

NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986

G

UNC homeobox

decreases expression

Phenytoin results in decreased expression of UNCX mRNA

NCBI chr12:15,092,779...15,097,300
Ensembl chr12:15,092,784...15,097,300

G

uracil-DNA glycosylase

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA

NCBI chr12:42,485,276...42,494,217
Ensembl chr12:42,485,276...42,494,206

G

valyl-tRNA synthetase 2, mitochondrial

increases expression

Phenytoin results in increased expression of VARS2 mRNA

NCBI chr20:3,077,132...3,087,994
Ensembl chr20:3,077,132...3,087,994

G

versican

increases expression

Phenytoin results in increased expression of VCAN mRNA

NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637

G

vascular endothelial growth factor B

decreases expression

Phenytoin results in decreased expression of VEGFB mRNA

NCBI chr 1:204,172,297...204,178,046
Ensembl chr 1:204,172,225...204,177,944

G

vimentin

increases expression

Phenytoin results in increased expression of VIM mRNA

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

Wnt family member 1

decreases expression

Phenytoin results in decreased expression of WNT1 mRNA

NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651

G

Wnt family member 3

decreases expression

Phenytoin results in decreased expression of WNT3 mRNA

NCBI chr10:88,680,198...88,724,170
Ensembl chr10:88,680,248...88,724,099

G

Wnt family member 5A

increases expression

Phenytoin results in increased expression of WNT5A mRNA

NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234

G

X-ray repair cross complementing 4

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA

NCBI chr 2:20,948,464...21,197,705
Ensembl chr 2:20,951,200...21,197,808

G

YME1-like 1 ATPase

increases expression

Phenytoin results in increased expression of YME1L1 mRNA

NCBI chr17:85,287,607...85,326,068
Ensembl chr17:85,287,554...85,326,335

G

zeta chain of T cell receptor associated protein kinase 70

decreases expression

Phenytoin results in decreased expression of ZAP70 mRNA

NCBI chr 9:38,989,750...39,011,701
Ensembl chr 9:38,989,750...39,011,700

G

zinc finger protein 131

increases expression

Phenytoin results in increased expression of ZFP131 mRNA

NCBI chr 2:51,722,774...51,753,662
Ensembl chr 2:51,725,541...51,753,639

G

zinc finger protein 503

increases expression

Phenytoin results in increased expression of ZFP503 mRNA

NCBI chr15:2,313,060...2,316,848
Ensembl chr15:2,313,060...2,316,848

G

zinc finger protein 638

increases expression

Phenytoin results in increased expression of ZFP638 mRNA

NCBI chr 4:116,355,934...116,475,051
Ensembl chr 4:116,402,428...116,479,845

G

zinc finger and SCAN domain containing 21

increases expression

Phenytoin results in increased expression of ZSCAN21 mRNA

NCBI chr12:16,998,496...17,024,167
Ensembl chr12:16,998,538...17,013,506

sertindole

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity
multiple interactions

sertindole results in decreased activity of KCNH2 protein
sertindole inhibits the reaction [KCNH2 protein results in increased transport of Thallium]

PMID:16278312 PMID:21158687 PMID:24052561

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

sorbinil

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions

sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of ACTA2 mRNA]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

aldo-keto reductase family 1 member B1

decreases activity
multiple interactions

sorbinil results in decreased activity of AKR1B1 protein
[sorbinil results in decreased activity of AKR1B1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Reactive Oxygen Species]; [sorbinil results in decreased activity of AKR1B1 protein] inhibits the reaction [Lipopolysaccharides results in increased secretion of Dinoprostone]; [sorbinil results in decreased activity of AKR1B1 protein] which results in decreased susceptibility to Lipopolysaccharides; [sorbinil results in decreased activity of AKR1B1 protein] which results in decreased susceptibility to TNF protein; sorbinil inhibits the reaction [AKR1B1 protein results in decreased expression of CDH1 mRNA]; sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of ACTA2 mRNA]; sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of FN1 mRNA]; sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of FN1 protein]; sorbinil inhibits the reaction [AKR1B1 protein results in increased phosphorylation of MAPK1 protein]; sorbinil inhibits the reaction [AKR1B1 protein results in increased phosphorylation of MAPK3 protein]

PMID:21334316 PMID:28137510

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1 member B10

multiple interactions
decreases activity

sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde]
sorbinil results in decreased activity of AKR1B10 protein

PMID:18325492 PMID:19028477

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

albumin

multiple interactions

sorbinil inhibits the reaction [[ALB protein binds to Fructosamine] which results in increased secretion of TNF protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

cadherin 1

multiple interactions

sorbinil inhibits the reaction [AKR1B1 protein results in decreased expression of CDH1 mRNA]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

fibronectin 1

multiple interactions

sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of FN1 mRNA]; sorbinil inhibits the reaction [AKR1B1 protein results in increased expression of FN1 protein]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

interleukin 6

multiple interactions

sorbinil inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; sorbinil inhibits the reaction [TNF protein results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

mitogen activated protein kinase 1

multiple interactions

sorbinil inhibits the reaction [AKR1B1 protein results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

sorbinil inhibits the reaction [AKR1B1 protein results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

nerve growth factor

multiple interactions

sorbinil inhibits the reaction [Streptozocin results in increased expression of NGF mRNA]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nitric oxide synthase 2

multiple interactions

sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

prostaglandin-endoperoxide synthase 2

multiple interactions

sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA]; sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]; sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

tachykinin, precursor 1

multiple interactions

sorbinil inhibits the reaction [Streptozocin results in increased expression of TAC1 mRNA]

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

tumor necrosis factor

multiple interactions

[sorbinil results in decreased activity of AKR1B1 protein] which results in decreased susceptibility to TNF protein; sorbinil inhibits the reaction [[ALB protein binds to Fructosamine] which results in increased secretion of TNF protein]; sorbinil inhibits the reaction [TNF protein results in increased abundance of Reactive Oxygen Species]; sorbinil inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]; sorbinil inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; sorbinil inhibits the reaction [TNF protein results in increased secretion of IL6 protein]
sorbinil inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; sorbinil inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein]

PMID:21334316 PMID:24021941 PMID:30682331

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular endothelial growth factor A

multiple interactions

sorbinil inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19831
chemical entity	19829
atom	19829
nonmetal atom	19767
nitrogen atom	18955
nitrogen molecular entity	18955
organonitrogen compound	18804
organonitrogen heterocyclic compound	18148
diazolidine	1017
imidazolidines	1007
(3S)-3-hydroxy-L-enduracididine	0
2-[1-(4-chlorophenyl)-5-oxo-3-(2-pyridin-4-ylethyl)-2-sulfanylidene-4-imidazolidinyl]-N-(4-fluorophenyl)acetamide	0
3-(2-fluorophenyl)-2-(4-fluorophenyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(2-methylphenyl)-2-(2-thiazolyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(3-bromophenyl)-2-(4-fluorophenyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(4-methoxyphenyl)-2-sulfanylidene-5-(thiophen-2-ylmethylidene)-4-imidazolidinone	0
4-(6-imidazolidin-2-yl-1H,3'H-2,5'-bibenzimidazol-2'-yl)phenol	0
4-chloro-N-[3-(4-fluorophenyl)-5-[2-(4-methoxyanilino)-2-oxoethyl]-4-oxo-2-sulfanylidene-1-imidazolidinyl]benzamide	0
8-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one	0
Alchorneine	0
Aniquinazoline A	0
Aniquinazoline B	0
Aniquinazoline C	0
Clazolimine	0
Ethylenethiourea	55
Imicyafos	0
L-enduracididine	0
N-(3-chlorophenyl)-5-oxo-9b-phenyl-2,3-dihydroimidazo[2,1-a]isoindole-1-carboxamide	0
N-(4-ethoxyphenyl)-2-[5-oxo-1-phenyl-3-(2-pyridinylmethyl)-2-sulfanylidene-4-imidazolidinyl]acetamide	0
[(2R,2'S)-2,2'-bipiperidinato(2-)-kappa(2)N(1),N(1')](imidazolidin-1-yl)[(6S)-6-[(2S)-piperidin-2-yl-kappaN]-1,2,3,6-tetrahydropyridinato(2-)-kappaN]ruthenium(2+)	0
bisantrene	0
imidacloprid +	412
imidapril +	5
imidaprilat	2
imidazolidine +	0
imidazolidinone +	613
methylparabanic acid	0
nimazone	0
Path 2
Term	Annotations
CHEBI ontology	19831
subatomic particle	19829
composite particle	19829
hadron	19829
baryon	19829
nucleon	19829
atomic nucleus	19829
atom	19829
main group element atom	19779
p-block element atom	19779
carbon group element atom	19728
carbon atom	19724
organic molecular entity	19724
organic molecule	19677
organic cyclic compound	19490
organic heterocyclic compound	18852
organic heteromonocyclic compound	17794
diazolidine	1017
imidazolidines	1007
(3S)-3-hydroxy-L-enduracididine	0
2-[1-(4-chlorophenyl)-5-oxo-3-(2-pyridin-4-ylethyl)-2-sulfanylidene-4-imidazolidinyl]-N-(4-fluorophenyl)acetamide	0
3-(2-fluorophenyl)-2-(4-fluorophenyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(2-methylphenyl)-2-(2-thiazolyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(3-bromophenyl)-2-(4-fluorophenyl)-5,6,7,7a-tetrahydro-3H-pyrrolo[1,2-c]imidazol-1-one	0
3-(4-methoxyphenyl)-2-sulfanylidene-5-(thiophen-2-ylmethylidene)-4-imidazolidinone	0
4-(6-imidazolidin-2-yl-1H,3'H-2,5'-bibenzimidazol-2'-yl)phenol	0
4-chloro-N-[3-(4-fluorophenyl)-5-[2-(4-methoxyanilino)-2-oxoethyl]-4-oxo-2-sulfanylidene-1-imidazolidinyl]benzamide	0
8-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one	0
Alchorneine	0
Aniquinazoline A	0
Aniquinazoline B	0
Aniquinazoline C	0
Clazolimine	0
Ethylenethiourea	55
Imicyafos	0
L-enduracididine	0
N-(3-chlorophenyl)-5-oxo-9b-phenyl-2,3-dihydroimidazo[2,1-a]isoindole-1-carboxamide	0
N-(4-ethoxyphenyl)-2-[5-oxo-1-phenyl-3-(2-pyridinylmethyl)-2-sulfanylidene-4-imidazolidinyl]acetamide	0
[(2R,2'S)-2,2'-bipiperidinato(2-)-kappa(2)N(1),N(1')](imidazolidin-1-yl)[(6S)-6-[(2S)-piperidin-2-yl-kappaN]-1,2,3,6-tetrahydropyridinato(2-)-kappaN]ruthenium(2+)	0
bisantrene	0
imidacloprid +	412
imidapril +	5
imidaprilat	2
imidazolidine +	0
imidazolidinone +	613
methylparabanic acid	0
nimazone	0

paths to the root